メディシナルケミストリー分野

352  件  
※ 登録方法の違いにより重複して表示されている場合があります。

  1. Kobayakawa T, Tsuji K, Tamamura H: Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres. Bioorganic & medicinal chemistry. 2024.08; 110 117811. ( PubMed , DOI )

  2. Tsuji K, Tamamura H, Burke TR Jr: Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. RSC chemical biology. 2024.07; 5 (8): 721-728. ( PubMed , DOI )

  3. Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, Tsuji K, Ohashi N, Yoshimura K, Nomura W, Mitsuya H, Maeda K, Tamamura H: Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS infectious diseases. 2024.05; 10 (6): 2250-2261. ( PubMed , DOI )

  4. Kobayakawa Takuya, Yokoyama Masaru, Tsuji Kohei, Boku Sayaka, Kurakami Masaki, Fujino Masayuki, Ishii Takahiro, Miura Yutaro, Nishimura Soshi, Shinohara Kouki, Yamamoto Kenichi, Bolah Peter, Kotani Osamu, Murakami Tsutomu, Sato Hironori, Tamamura Hirokazu: Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins(タイトル和訳中) Chemical & Pharmaceutical Bulletin. 2024.01; 72 (1): 41-47. ( 医中誌 )

  5. Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, Ishii T, Miura Y, Nishimura S, Shinohara K, Yamamoto K, Bolah P, Kotani O, Murakami T, Sato H, Tamamura H: Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins. Chemical & pharmaceutical bulletin. 2024; 72 (1): 41-47. ( PubMed , DOI )

  6. Tsuji K, Tamamura H, Burke TR Jr: Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3. Biological & pharmaceutical bulletin. 2024; 47 (7): 1282-1287. ( PubMed , DOI )

  7. Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, Nomura W, Furuta T, Tamamura H: Effect of Two-Photon Excitation to 8-Azacoumarin Derivatives as Photolabile Protecting Groups. Chemical & pharmaceutical bulletin. 2024; 72 (3): 311-312. ( PubMed , DOI )

  1. Kohei Tsuji, Takuya Kobayakawa, Takahiro Ishii, Nobuyo Higashi-Kuwata, Chika Azuma, Kouki Shinohara, Yutaro Miura, Kenichi Yamamoto, Soshi Nishimura, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura: Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement. Chemical and Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( PubMed , DOI )

  2. Tsuji Kohei, Kobayakawa Takuya, Ishii Takahiro, Higashi-Kuwata Nobuyo, Azuma Chika, Shinohara Kouki, Miura Yutaro, Yamamoto Kenichi, Nishimura Soshi, Hattori Shin-ichiro, Bulut Haydar, Mitsuya Hiroaki, Tamamura Hirokazu: Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement(タイトル和訳中) Chemical & Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( 医中誌 )

  3. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Shinohara K, Azuma C, Miura Y, Nakano H, Wada N, Hattori SI, Bulut H, Mitsuya H, Tamamura H: Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties. Journal of medicinal chemistry. 2023.09; 66 (19): 13516-13529. ( PubMed , DOI )

  4. Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kohei Tsuji, Nami Ohashi, Shingo Nakahata, Airi Noborio, Kazuhisa Yoshimura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura: Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity. European Journal of Medicinal Chemistry. 2023.08; 256 115449. ( PubMed , DOI )

  5. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Yutaro Miura, Takahiro Ishii, Kouki Shinohara, Takuya Kobayakawa, Akino Emi, Takashi Nakano, Youichi Suzuki, Hirokazu Tamamura : Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2 RSC Advances. 2023.03; 13 8779-8793.

  6. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H: Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023.02; 14 (1): 1076. ( PubMed , DOI )

  7. Kitamura H., Sukegawa S., Matsuda K., Tanimoto K., Kobayakawa T., Takahashi K., Tamamura H., Tsuchiya K., Gatanaga H., Maeda K., and Takeuchi H.: 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells. Biochemical and Biophysical Research Communications. 2023.01; 641 139-147. ( PubMed , DOI )

  1. Rongyi Wang, Kohei Tsuji, Takuya Kobayakawa, Yishan Liu, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura: Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors Bioorganic & Medicinal Chemistry. 2022.12; 76 117083. ( PubMed , DOI )

  2. Matsumoto K, Kuwata T, Tolbert WD, Richard J, Ding S, Prévost J, Takahama S, Judicate GP, Ueno T, Nakata H, Kobayakawa T, Tsuji K, Tamamura H, Smith AB 3rd, Pazgier M, Finzi A, Matsushita S: Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates. Journal of virology. 2022.12; 97 (1): e0163822. ( PubMed , DOI )

  3. Matsuura K, Yamaura M, Sakawaki H, Himeno A, Pisil Y, Kobayakawa T, Tsuji K, Tamamura H, Matsushita S, Miura T: Sensitivity to a CD4 mimic of a consensus clone of monkey-adapted CCR5-tropic SHIV-MK38C. Virology. 2022.12; 578 171-179. ( PubMed , DOI )

  4. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H: Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022.11; 105365. ( PubMed , DOI )

  5. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H: Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022.11; 105365. ( PubMed , DOI )

  6. Kohei Tsuji, David Hymel, Buyong Ma, Hirokazu Tamamura, Ruth Nussinov, Terrence R Burke Jr: Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1. RSC chemical biology. 2022.08; 3 (9): 1111-1120. ( PubMed , DOI )

  7. Tsuji K, Kobayakawa T, Konno K, Masuda A, Takahashi K, Ohashi N, Yoshimura K, Kuwata T, Matsushita S, Harada S, Tamamura H: Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors. Bioorganic & medicinal chemistry. 2022.01; 56 116616. ( PubMed , DOI )

  1. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nami Ohashi, Wataru Nomura & Hirokazu Tamamura: Fluorescence resonance energy transfer-based screening for protein kinase C ligands using 6-methoxynaphthalene-labeled 1,2-diacylglycerol-lactones. Organic & Biomolecular Chemistry. 2021.10; 19 (38): 8264-8271. ( PubMed , DOI )

  2. David Hymel, Kohei Tsuji, Robert A Grant, Ramesh M Chingle, Dominique L Kunciw, Michael B Yaffe, Terrence R Burke Jr: Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles. Organic & Biomolecular Chemistry. 2021.09; 19 (36): 7843-7854. ( PubMed , DOI )

  3. Hasan Md Zahid, Takeo Kuwata, Shokichi Takahama, Yu Kaku, Shashwata Biswas, Kaho Matsumoto, Hirokazu Tamamura & Shuzo Matsushita: Functional Analysis of a Monoclonal Antibody Reactive against the C1C2 of Env Obtained from a Patient Infected with HIV-1 CRF02_AG. Retrovirology. 2021.08; 18 (1): 23(article number).

  4. Jan Vincent V. Arafiles, Hisaaki Hirose, Yusuke Hirai, Masashi Kuriyama, Maxwell Mamfe Sakyiamah, Wataru Nomura, Kazuhiro Sonomura, Miki Imanishi, Akira Otaka, Hirokazu Tamamura & Shiroh Futaki: Discovery of a Macropinocytosis-inducing Peptide Potentiated by Medium-mediated Intramolecular Disulfide Formation. Angewandte Chemie International Edition. 2021.05; 60 (21): 11928-11936.

  5. Takuya Kobayakawa, Chika Azuma, Yuki Watanabe, Shunsuke Sawamura, Atsuhiko Taniguchi, Yoshio Hayashi, Kohei Tsuji & Hirokazu Tamamura: Development of Methods for Convergent Synthesis of Chloroalkene Dipeptide Isosteres and Its Application. The Journal of Organic Chemistry. 2021.03; 86 (7): 5091-5101. ( PubMed , DOI )

  6. Takuya Kobayakawa, Masaru Yokoyama, Kohei Tsuji, Masayuki Fujino, Masaki Kurakami, Sayaka Boku, Miyuki Nakayama, Moemi Kaneko, Nami Ohashi, Osamu Kotani, Tsutomu Murakami, Hironori Sato & Hirokazu Tamamura: Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins. Biomolecules. 2021.02; 11 (2): 208. ( PubMed , DOI )

  7. Takuya Kobayakawa, Kohei Tsuji, Kiju Konno, Ai Himeno, Ami Masuda, Tingting Yang, Kohei Takahashi, Yusuke Ishida, Nami Ohashi, Takeo Kuwata, Kaho Matsumoto, Kazuhisa Yoshimura, Hiromi Sakawaki, Tomoyuki Miura, Shigeyoshi Harada, Shuzo Matsushita & Hirokazu Tamamura: Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors. Journal of Medicinal Chemistry. 2021.01; 64 (3): 1481-1496. ( PubMed , DOI )

  8. Kohei Tsuji, Rongyi Wang, Takuya Kobayakawa, Kofi Baffour-Awuah Owusu, Masayuki Fujino, Moemi Kaneko, Naoki Yamamoto, Tsutomu Murakami, Hirokazu Tamamura: Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment. Bioorganic & Medicinal Chemistry. 2021.01; 30 115923. ( PubMed , DOI )

  9. Kouki Matsuda, Takuya Kobayakawa, Ryusho Kariya, Kiyoto Tsuchiya, Kohei Tsuji, Takahiro Ishii, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Seiji Okada, Hiroaki Mitsuya, Hirokazu Tamamura & Kenji Maeda: A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators. Frontiers in Microbiology. 2021; 12 636276. ( PubMed , DOI )

  10. Takuya Kobayakawa, Hirokazu Tamamura: Chloroalkene dipeptide isosteres as peptidomimetics. Methods in enzymology. 2021; 656 191-239. ( PubMed , DOI )

  1. Takuya Kobayakawa, Kento Ebihara, Kohei Tsuji, Takuma Kawada, Masayuki Fujino, Yuzuna Honda, Nami Ohashi, Tsutomu Murakami, Hirokazu Tamamura: Bivalent HIV-1 fusion inhibitors based on peptidomimetics. Bioorg. Med. Chem. 2020.12; 28 (24): 115812. ( PubMed , DOI )

  2. Stephen E. Miller, Kohei Tsuji, Rachel P.M. Abrams, Terrence R. Burke, Jr., Joel P. Schneider: Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions. J. Am. Chem. Soc. 2020.11; 142 (47): 19950-19955. ( PubMed , DOI )

  3. Daisuke Matsumoto, Hirokazu Tamamura, Wataru Nomura: A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy Communications Biology. 2020.10; 3 1-10. ( PubMed , DOI )

  4. Kohei Tsuji, David Hymel, Terrence R. Burke, Jr.: A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. Anal. Methods: advancing methods and applications. 2020.09; 12 (36): 4418-4421. ( PubMed , DOI )

  5. Junpeng Qi, Kohei Tsuji, David Hymel, Terrence R. Burke, Jr., Michael Hudecek, Christoph Rader, Haiyong Peng: Chemically Programmable and Switchable CAR-T Therapy Angew. Chem., Int. Ed. 2020.07; 59 (29): 12178-12185 . ( PubMed , DOI )

  6. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Takuya Kobayakawa, Rongyi Wang, Masayuki Fujino, Moemi Kaneko, Naoki Yamamoto, Tsutomu Murakami, Hirokazu Tamamura: Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment. Bioorg. Med. Chem. 2020.06; 28 (11): 115488. ( PubMed , DOI )

  7. Takuya Kobayakawa, Hikaru Takano, Takahiro Ishii, Kohei Tsuji, Nami Ohashi, Wataru Nomura, Toshiaki Furuta, Hirokazu Tamamura: Synthesis of hydrophilic caged DAG-lactones for chemical biology applications. Org. Biomol. Chem. 2020.05; 18 (22): 4217-4223 . ( PubMed , DOI )

  8. Daisuke Matsumoto, Hirokazu Tamamura, Wataru Nomura: TALEN-Based Chemically Inducible, Dimerization-Dependent, Sequence-Specific Nucleases Biochemistry . 2020.01; 59 (2): 197-204. ( PubMed , DOI )

  1. Maeda Kenji, Matsuda Kouki, Islam Saiful, Kobayakawa Takuya, Tsuchiya Kiyoto, Hattori Shin-ichiro, Gatanaga Hiroyuki, Oka Shinichi, Yoshimura Kazuhisa, Tamamura Hirokazu, Mitsuya Hiroaki, Satou Yorifumi: HIV持続潜伏感染に関する最先端研究(Treatment of HIV-1-reservoirs using latency-reversing agents(LRAs) toward HIV cure) 日本エイズ学会誌. 2019.11; 21 (4): 314. ( 医中誌 )

  2. Hwang D, Tsuji K, Park H, Burke TR Jr, Rader C: Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. Bioconjugate chemistry. 2019.11; 30 (11): 2889-2896. ( PubMed , DOI )

  3. Mohammad Mamun Alam, Takeo Kuwata, Kazuki Tanaka, Muntasir Alam, Shokichi Takahama, Kazuya Shimura, Masao Matsuoka, Natsuki Fukuda, Hiroshi Morioka, Hirokazu Tamamura, Shuzo Matsushita: Synergistic Inhibition of Cell-to-cell HIV-1 Infection by Combinations of Single Chain Variable Fragments and Fusion Inhibitors Biochem Biophys Rep.. 2019.09; 20 100687.

  4. Takuya Kobayakawa, Kento Ebihara, Yuzuna Honda, Masayuki Fujino, Wataru Nomura, Naoki Yamamoto, Tsutomu Murakami, Hirokazu Tamamura: Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors. Chembiochem. 2019.08; 20 (16): 2101-2108. ( PubMed , DOI )

  5. Kenji Maeda, Debananda Das, Takuya Kobayakawa, Hirokazu Tamamura, Hiroaki Takeuchi: Discovery and Development of anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Current topics in medicinal chemistry. 2019.07; 19 (18): 1621-1649. ( PubMed , DOI )

  6. Kawahara Haruka, Miyashita Naoki, Tachibana Koki, Tsuda Yusuke, Morimoto Kyohei, Tsuji Kohei, Shigenaga Akira, Otaka Akira, Ishida Tatsuhiro, Okuhira Keiichiro: A Photo-Activatable Peptide Mimicking Functions of Apolipoprotein A-I BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2019.06; 42 (6): 1019-1024.

  7. Maxwell M Sakyiamah, Wataru Nomura, Takuya Kobayakawa, Hirokazu Tamamura: Development of a NanoBRET-Based Sensitive Screening Method for CXCR4 Ligands. Bioconjug. Chem.. 2019.05; 30 (5): 1442-1450. ( PubMed , DOI )

  8. Zhao XZ, Tsuji K, Hymel D, Burke TR Jr: Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules (Basel, Switzerland). 2019.04; 24 (8): 1488. ( PubMed , DOI )

  9. Takuya Kobayakawa, Kiju Konno, Nami Ohashi, Kohei Takahashi, Ami Masuda, Kazuhisa Yoshimura, Shigeyoshi Harada, Hirokazu Tamamura: Soluble-type small-molecule CD4 mimics as HIV entry inhibitors BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2019.03; 29 (5): 719-723. ( PubMed , DOI )

  10. Hogan M, Bahta M, Tsuji K, Nguyen TX, Cherry S, Lountos GT, Tropea JE, Zhao BM, Zhao XZ, Waugh DS, Burke TR Jr, Ulrich RG: Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds. ACS combinatorial science. 2019.03; 21 (3): 158-170. ( PubMed , DOI )

  11. Maxwell M. Sakyiamah, Takuya Kobayakawa, Masayuki Fujino, Makoto Konno, Tetsuo Narumi, Tomohiro Tanaka, Wataru Nomura, Naoki Yamamoto, Tsutomu Murakami, Hirokazu Tamamura: Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands BIOORGANIC & MEDICINAL CHEMISTRY. 2019.03; 27 (6): 1130-1138. ( PubMed , DOI )

  12. Akinobu Z. Suzuki, Ryota Sekine, Shiori Takeda, Ryosuke Aikawa, Yukiko Shiraishi, Tomomi Hamaguchi, Hiroyuki Okuno, Tamamura Hirokazu, Furuta Toshiaki: A clickable caging group as a new platform for modular caged compounds with improved photochemical properties CHEMICAL COMMUNICATIONS. 2019.01; 55 (4): 451-454. ( PubMed , DOI )

  13. Kouki Matsuda, Takuya Kobayakawa, Kiyoto Tsuchiya, Shin-Ichiro Hattori, Wataru Nomura, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Shinichi Oka, Yasuyuki Endo, Hirokazu Tamamura, Hiroaki Mitsuya, Kenji Maeda: Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal. J. Biol. Chem.. 2019.01; 294 (1): 116-129. ( PubMed , DOI )

  1. Takuya Kobayakawa, Nami Ohashi, Yuki Hirota, Kohei Takahashi, Yuko Yamada, Tetsuo Narumi, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura: Flexibility of small molecular CD4 mimics as HIV entry inhibitors. Bioorg. Med. Chem.. 2018.11; 26 (21): 5664-5671. ( PubMed , DOI )

  2. Wataru Nomura, Daisuke Matsumoto, Taisuke Sugii, Takuya Kobayakawa, Hirokazu Tamamura: Efficient and Orthogonal Transcription Regulation by Chemically Inducible Artificial Transcription Factors. Biochemistry. 2018.11; 57 (45): 6452-6459. ( PubMed , DOI )

  3. Hymel D, Grant RA, Tsuji K, Yaffe MB, Burke TR Jr: Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorganic & medicinal chemistry letters. 2018.10; 28 (19): 3202-3205. ( PubMed , DOI )

  4. Kei Toyama, Wataru Nomura, Takuya Kobayakawa, Hirokazu Tamamura: Delivery of a Proapoptotic Peptide to EGFR-Positive Cancer Cells by a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR. Bioconjug. Chem.. 2018.06; 29 (6): 2050-2057. ( PubMed , DOI )

  5. Wataru Nomura, Daisuke Matsumoto, Taisuke Sugii, Takuya Kobayakawa: Chemically-controlled orthogonal regulation of multiple endogenous genes FASEB Journal. 2018.04; 32 (1):

  6. Takuya Kobayakawa, Yudai Matsuzaki, Kentaro Hozumi, Wataru Nomura, Motoyoshi Nomizu, Hirokazu Tamamura: Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application. ACS Medicinal Chemistry Letters. 2018.01; 9 (1): 6-10. ( PubMed , DOI )

  7. Kei Toyama, Takuya Kobayakawa, Wataru Nomura, Hirokazu Tamamura: Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR. Chem. Pharm. Bull.. 2018; 66 (11): 1083-1089. ( PubMed , DOI )

  1. Tanegashima Kosuke, Takahashi Rena, Nuriya Hideko, Iwase Rina, Naruse Naoto, Tsuji Kohei, Shigenaga Akira, Otaka Akira, Hara Takahiko: CXCL14 Acts as a Specific Carrier of CpG DNA into Dendritic Cells and Activates Toll-like Receptor 9-mediated Adaptive Immunity EBIOMEDICINE. 2017.10; 24 247-256. ( PubMed , DOI )

  2. Nomura Wataru, Matsumoto Daisuke, Hashimoto Tsukasa, Sugii Taisuke, Tamamura Hirokazu: Development of chemical-inducible artificial transcription factors based on sequence-specific DNA binders ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2017.08; 254

  3. Ohashi N, Kobayashi R, Nomura W, Kobayakawa T, Czikora A, Herold B K, Lewin N E, Blumberg P M, Tamamura H: Synthesis and Evaluation of Dimeric Derivatives of Diacylglycerol-Lactones as Protein Kinase C Ligands. Bioconjugate Chem. 2017.07; ( DOI )

  4. Takuya Kobayakawa, Hirokazu Tamamura: Stereoselective synthesis of Xaa-Yaa type (Z)-chloroalkene dipeptide isosteres via efficient utilization of organocopper reagents mediated allylic alkylation Tetrahedron. 2017.07; 73 (30): 4464-4471. ( DOI )

  5. Kobayakawa Takuya, Tamamura Hirokazu: Stereoselective synthesis of Xaa-Yaa type (Z)-chloroalkene dipeptide isosteres via efficient utilization of organocopper reagents mediated allylic alkylation TETRAHEDRON. 2017.07; 73 (30): 4464-4471. ( DOI )

  6. Kobayashi K, Mizuguchi T, Hattori Y, Ohara N, Ninomiya R, Iida M, Ooe H, Yamazaki Y, Takata M, Tamamura H, Akaji K: Effects of Replacement and Addition of an Amino Acid Contained in a Cyclic Peptide Corresponding to a β-Hairpin Loop Sequence of Human EGF Receptor. J. Pept. Sci. 2017.04; ( DOI )

  7. Takuya Kobayakawa: Synthetic Studies on Chloroalkene Dipeptide Isosteres as Peptidomimetics 国立大学法人 東京医科歯科大学. 2017.03;

  8. Takano Hikaru, Narumi Tetsuo, Nomura Wataru, Tamamura Hirokazu: Microwave-Assisted Synthesis of Azacoumarin Fluorophores and the Fluorescence Characterization JOURNAL OF ORGANIC CHEMISTRY. 2017.03; 82 (5): 2739-2744. ( PubMed , DOI )

  9. Takano T, Narumi T, Nomura W, Tamamura H: Microwave-Assisted Synthesis of Azacoumarin Fluorophores and the Fluorescence Characterization. J. Org. Chem. 2017.02; 82 (5): 2739-2744.

  10. Tanaka T, Aoki T, Nomura W, Tamamura H : Bivalent 14-mer Peptide Ligands of CXCR4 with Polyproline Linkers with Anti-Chemotactic Activity against Jurkat Cells. J. Pept. Sci. 2017.01; ( DOI )

  11. Mizuguchi T, Ohashi N, Matsumoto D, Hashimoto C, Nomura W, Yamamoto N, Murakami T, Tamamura: Development of Anti-HIV Peptides Based on a Viral Capsid Protein. Biopolymers: Peptide Science. 2017.01; 108 (1): ( DOI )

  1. Takuya Kobayakawa, Hirokazu Tamamura: Efficient synthesis of Xaa-Gly type (Z)-chloroalkene dipeptide isosteres via organocuprate mediated reduction Tetrahedron. 2016.08; 72 (32): 4968-4971. ( DOI )

  2. Kobayakawa Takuya, Tamamura Hirokazu: Development of synthetic methodology of chloroalkene-type dipeptide isosteres for peptidomimetics ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2016.08; 252

  3. Mitsuhiro Eto, Naoto Naruse, Kyohei Morimoto, Kosuke Yamaoka, Kohei Sato, Kohei Tsuji, Tsubasa Inokuma, Akira Shigenaga, Akira Otaka: Development of an Anilide-Type Scaffold for the Thioester Precursor N-Sulfanylethylcoumarinyl Amide. Org. Lett.. 2016.08; 18 (17): 4416-4419. ( PubMed , DOI )

  4. Takuya Kobayakawa, Tetsuo Narumi, Hirokazu Tamamura: Stereoselective Synthesis of Chloroalkene Dipeptide Isosteres Utilizing Organocopper Reagents PEPTIDE SCIENCE 2015. 2016.03; 97-98.

  5. Ohashi N, Harada S, Mizuguchi T, Irahara Y, Yamada Y, Kotani M, Nomura W, Matsushita S, Yoshimura K, Tamamura H: Small Molecular CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors. ChemMedChem a joint special issue with ChemBioChem: Protein–Protein Interactions. 2016; 11 (8): 940-946.

  6. Hiramatsu K, Tamamura H: A Mild Method for the Direct Fluorination of Pyrroles by Using a Lipophilic Anionic Phase-Transfer Catalyst. Eur. J. Org. Chem. 2016; 21 3491-3494.

  7. Toyama K, Mizuguchi T, Nomura W, Tamamura H: Functional Evaluation of Fluorescein-Labeled Derivatives of a Peptide Inhibitor of the EGF Receptor Dimerization Bioorg. Med. Chem. 2016; 24 (16): 3406-3412.

  8. Mizuguchi T, Harada S, Miura T, Ohashi N, Narumi T, Mori H, Irahara Y, Yamada Y, Nomura W, Matsushita S, Yoshimura K, Tamamura H: A Minimally Cytotoxic CD4 Mimic as an HIV Entry Inhibitor Bioorg. Med. Chem. Lett . 2016; 2 (26): 397-400.

  9. Abduelmula A, Huang R, Pu Q, Tamamura H, Puopolo G. M & Saberi B. B: SDF-1 Controls the Muscle and Blood Vessel Formation of the Somite. Int. J. Dev. Biol. 2016; 60(1-2-3) (29-38):

  10. Takano H, Narumi T, Nomura W, Tamamura H: Microwave-Assisted Synthesis of Azacoumarin Fluorophores and the Fluorescence Characterization J. Org. Chem. 2016; in press

  11. Nakamura T, Campbell J.R, Moore A.R, Otsu S, Aikawa H, Tamamura H, Mitsuya H: Development and Validation of a Cell-based Assay System to Assess Human Immunodeficiency Virus Type 1 Integrase Multimerization J. Virol. Methods. 2016; 236 196-206.

  12. Nomura W, Mizuguchi T & Tamamura H: Multimerized HIV-gp41-derived Peptides as Fusion Inhibitors and Vaccines Biopolymers: Peptide Science. 2016; 106 (4): 622-628.

  1. Wataru Nomura, Takaaki Mizuguchi & Hirokazu Tamamura: Multimerized HIV-gp41-derived Peptides as Fusion Inhibitors and Vaccines Biopolymers: Peptide Science. 2015.11; ( DOI )

  2. Kohei Tsuji, Kosuke Tanegashima, Kohei Sato, Ken Sakamoto, Akira Shigenaga, Tsubasa Inokuma, Takahiko Hara, Akira Otaka: Efficient one-pot synthesis of CXCL14 and its derivative using an N-sulfanylethylanilide peptide as a peptide thioester equivalent and their biological evaluation. Bioorg. Med. Chem.. 2015.09; 23 (17): 5909-5914. ( PubMed , DOI )

  3. Chiharu Mizuguchi, Fuka Ogata, Shiho Mikawa, Kohei Tsuji, Teruhiko Baba, Akira Shigenaga, Toshinori Shimanouchi, Keiichiro Okuhira, Akira Otaka, Hiroyuki Saito: Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes. J. Biol. Chem.. 2015.08; 290 (34): 20947-20959. ( PubMed , DOI )

  4. Yusuke Tsuda, Akira Shigenaga, Kohei Tsuji, Masaya Denda, Kohei Sato, Keisuke Kitakaze, Takahiro Nakamura, Tsubasa Inokuma, Kohji Itoh, Akira Otaka: Development of a Chemical Methodology for the Preparation of Peptide Thioesters Applicable to Naturally Occurring Peptides Using a Sequential Quadruple Acyl Transfer System. ChemistryOpen. 2015.08; 4 (4): 448-452. ( PubMed , DOI )

  5. Takuya Kobayakawa, Tetsuo Narumi, Hirokazu Tamamura: Remote Stereoinduction in the Organocuprate-Mediated Allylic Alkylation of Allylic gem-Dichlorides: Highly Diastereoselective Synthesis of (Z)-Chloroalkene Dipeptide Isosteres. Organic Letters. 2015.05; 17 (10): 2302-2305. ( PubMed , DOI )

  6. Takuya Kobayakawa, Tetsuo Narumi, Hirokazu Tamamura: Development of Efficient Synthetic Methodologies of Chloroalkene Dipeptide Isosteres PEPTIDE SCIENCE 2014. 2015.03; 13-14.

  7. Yuki Takechi-Haraya, Kento Tanaka, Kohei Tsuji, Yasuo Asami, Hironori Izawa, Akira Shigenaga, Akira Otaka, Hiroyuki Saito, Kohsaku Kawakami: Molecular complex composed of β-cyclodextrin-grafted Chitosan and pH-sensitive amphipathic peptide for enhancing cellular cholesterol efflux under acidic pH. Bioconjug. Chem.. 2015.03; 26 (3): 572-581. ( PubMed , DOI )

  8. Takano H, Narumi T, Nomura W, Furuta T, Tamamura H: Utilization of the Heavy Atom Effect for the Development of a Photosensitive 8-Azacoumarin-type Photolabile Protecting Group Org Lett. 2015; 21 (17): 5372-5375.

  9. Nomura W, Aikawa H, Taketomi S, Tanabe M, Mizuguchi T, Tamamura H: Exploration of Labeling of Near Infrared Dyes on the Polyproline Linker for Bivalent-Type CXCR4 Ligands Bioorg Med Chem. 2015; 21 (23): 6967-6973.

  10. Nomura W, Koseki T, Ohashi N, Mizuguchi T, Tamamura H: Trivalent Lignds for CXCR4 Bearing Polyproline Linkers Show Specific Recognition for Cells with Increased CXCR4 Expression. Org Biomol Chem. 2015; 32 (13): 8734-8739.

  11. Mizuguchi T, Ohashi N, Nomura W, Komoriya M, Hashimoto C, Yamamoto N, Murakami T, Tamamura H: Anti-HIV Screening for Cell-Penetrating Peptides Using Chloroquine and Identification of Anti-HIV Peptides Derived from Matrix Proteins. Bioorg Med Chem. 2015; 15 (23): 4423-4427.

  12. Nomura W, Ohashi N, Mori A, Tamamura H: An In-cell Fluorogenic Tag-probe System for Protein Dynamics Imaging Enabled by Cell-Penetrating Peptides. Bioconjugate Chem. 2015; 6 (26): 1080-1085.

  1. Emi Adachi, Asako Kosaka, Kohei Tsuji, Chiharu Mizuguchi, Hiroyuki Kawashima, Akira Shigenaga, Kohjiro Nagao, Kenichi Akaji, Akira Otaka, Hiroyuki Saito: The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett.. 2014.01; 588 (3): 389-394. ( PubMed , DOI )

  2. Nami Ohashi, Wataru Nomura, Natsuki Minato & Hirokazu Tamamura : Screening for Protein Kinase C Ligands Using Fluorescence Resonance Energy Transfer. Chem. Pharm. Bull., . 2014; 62 (10): 1019-1025.

  3. Tetsuo Narumi, Hikaru Takano, Nami Ohashi, Akinobu Suzuki, Toshiaki Furuta & Hirokazu Tamamura: Isostere-Based Design of 8-Azacoumarin-type Photolabile Protecting Groups: A Hydrophilicity Increasing Strategy for Coumarin-4-ylmethyls. Org. Lett.,. 2014; 16 (4): 1184-1187.

  4. Jun Yamamoto, Masaya Denda, Nami Maeda, Miku Kita, Chiaki Komiya, Tomohiro Tanaka, Wataru Nomura, Hirokazu Tamamura, Youichi Sato, Aiko Yamauchi, Akira Shigenaga & Akira Otaka: Development of a Traceable Linker Containing a Thiol-responsive Amino Acid for the Enrichment and Selective Labelling of Target Proteins. Org. Biomol. Chem.,. 2014; 12 (23): 3821-3826.

  5. Hikaru Takano, Tetsuo Narumi, Nami Ohashi, Akinobu Suzuki, Toshiaki Furuta, Wataru Nomura & Hirokazu Tamamura: Development of the 8-Aza-3-bromo-7-hydroxycoumarin-4-ylmethyl Group as a New Entry of Photolabile Protecting Groups. Tetrahedron, . 2014; 70 (29): 4400-4404.

  6. Jun Yamamoto, Nami Maeda, Chiaki Komiya, Tomohiro Tanaka, Masaya Denda, Koji Ebisuno, Wataru Nomura, Hirokazu Tamamura, Youichi Sato, Aiko Yamauchi, Akira Shigenaga & Akira Otaka: Development of a Fluoride-responsive Amide Bond Cleavage Device that is Potentially Applicable to a Traceable Linker. Tetrahedron,. 2014; 70 (34): 5122-5127.

  1. Kosuke Tanegashima#, Kohei Tsuji#, Kenji Suzuki, Akira Shigenaga, Akira Otaka, Takahiko Hara (#Equally contributed): Dimeric peptides of the C-terminal region of CXCL14 function as CXCL12 inhibitors. FEBS Lett.. 2013.11; 587 (23): 3770-3775. ( PubMed , DOI )

  2. Kosuke Tanegashima, Kenji Suzuki, Yuki Nakayama, Kohei Tsuji, Akira Shigenaga, Akira Otaka, Takahiko Hara: CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett.. 2013.06; 587 (12): 1731-1735. ( PubMed , DOI )

  3. Tetsuo Narumi, Haruo Aikawa, Tomohiro Tanaka, Chie Hashimoto, Nami Ohashi, Wataru Nomura, Takuya Kobayakawa, Hikaru Takano, Yuki Hirota, Tsutomu Murakami, Naoki Yamamoto, Hirokazu Tamamura: Low-molecular-weight CXCR4 ligands with variable spacers. ChemMedChem. 2013.01; 8 (1): 118-124. ( PubMed , DOI )

  4. Nami Ohashi, Wataru Nomura, Tetsuo Narumi & Hirokazu Tamamura: Peptide-based Ligand Screening and Functional Analysis of Protein Kinase C Biopolymers. 2013; 100 (6): 613-620.

  5. Tetsuo Narumi, Haruo Aikawa, Tomohiro Tanaka, Chie Hashimoto, Nami Ohashi, Wataru Nomura, Takuya Kobayakawa, Hikaru Takano, Yuki Hirota, Tsutomu Murakami, Naoki Yamamoto & Hirokazu Tamamura: Low Molecular Weight CXCR4 Ligands with Variable Spacers. ChemMedChem,. 2013; 8 (1): 118-124.

  6. Tetsuo Narumi, Hiroshi Arai, Kazuhisa Yoshimura, Shigeyoshi Harada, Yuki Hirota, Nami Ohashi, Chie Hashimoto, Wataru Nomura, Shuzo Matsushita & Hirokazu Tamamura: CD4 Mimics as HIV Entry Inhibitors: Lead Optimization Studies of the Aromatic Substituents. Bioorg. Med. Chem.,. 2013; 21 (9): 2518-2526.

  7. Wataru Nomura, Chie Hashimoto, Takaharu Suzuki, Nami Ohashi, Masayuki Fujino, Tsutomu Murakami, Naoki Yamamoto & Hirokazu Tamamura: Multimerized CHR-derived Peptides as HIV-1 Fusion Inhibitors. Bioorg. Med. Chem.,. 2013; 21 (15): 4452-4458.

  8. Chie Hashimoto, Wataru Nomura, Tetsuo Narumi, Masayuki Fujino, Hiroshi Tsutsumi, Masaki Haseyama, Naoki Yamamoto, Tsutomu Murakami & Hirokazu Tamamura: Anti-HIV-1 Peptide Derivatives Based on the HIV-1 Co-receptor CXCR4. ChemMedChem,. 2013; 8 (10): 1668-1672.

  9. Wataru Nomura, Haruo Aikawa, Nami Ohashi, Emiko Urano, Mathieu Metifiot, Masayuki Fujino, Kasthuraiah Maddali, Taro Ozaki, Ami Nozue, Tetsuo Narumi, Chie Hashimoto, Tomohiro Tanaka, Yves Pommier, Naoki Yamamoto, Jun Komano, Tsutomu Murakami & Hirokazu Tamamura: Cell-Permeable Stapled Peptides Based on HIV-1 Integrase Inhibitors Derived from HIV-1 Gene Product. ACS Chem. Biol.,. 2013; 8 (10): 2235-2244.

  10. Hiroyuki Otsuki, Takayuki Hishiki, Tomoyuki Miura, Chie Hashimoto, Tetsuo Narumi, Hirokazu Tamamura, Kazuhisa Yoshimura, Shuzo Matsushita & Tatsuhiko Igarashi: Generation of a Replication-competent Simian–human Immunodeficiency Virus, the Neutralisation Sensitivity of Which can be Enhanced in the Presence of a Small Molecule CD4 Mimic. J. Gen. Virol.,. 2013; 94 (12): 2710-2716.

  11. Chie Hashimoto, Wataru Nomura, Tetsuo Narumi, Masayuki Fujino, Toru Nakahara, Naoki Yamamoto, Tsutomu Murakami & Hirokazu Tamamura: CXCR4-derived Synthetic Peptides Inducing Anti-HIV-1 Antibodies. Bioorg. Med. Chem.,. 2013; 21 (22): 6878-6885.

  12. Chie Hashimoto, Tetsuo Narumi, Hiroyuki Otsuki, Yuki Hirota, Hiroshi Arai, Kazuhisa Yoshimura, Shigeyoshi Harada, Nami Ohashi, Wataru Nomura, Tomoyuki Miura, Tatsuhiko Igarashi, Shuzo Matsushita & Hirokazu Tamamura: A CD4 Mimic as an HIV Entry Inhibitor: Pharmacokinetics. Bioorg. Med. Chem.,. 2013; 21 (24): 7884-7889.

  1. Tetsuo Narumi, Takuya Kobayakawa, Haruo Aikawa, Shunsuke Seike, Hirokazu Tamamura: Stereoselective formation of trisubstituted (Z)-chloroalkenes adjacent to a tertiary carbon stereogenic center by organocuprate-mediated reduction/alkylation. Organic Letters. 2012.09; 14 (17): 4490-4493. ( PubMed , DOI )

  2. Ken Sakamoto, Kohei Sato, Akira Shigenaga, Kohei Tsuji, Shugo Tsuda, Hajime Hibino, Yuji Nishiuchi, Akira Otaka: Synthetic procedure for N-Fmoc amino acyl-N-sulfanylethylaniline linker as crypto-peptide thioester precursor with application to native chemical ligation. J. Org. Chem.. 2012.08; 77 (16): 6948-6958. ( PubMed , DOI )

  3. Narumi T, Tanaka T, Hashimoto C, Nomura W, Aikawa H, Sohma A, Itotani K, Kawamata M, Murakami T, Yamamoto N, Tamamura H: Pharmacophore-based small molecule CXCR4 ligands. Bioorg Med Chem Lett. 2012.06; 22 (12): 4169-4172. ( PubMed , DOI )

  4. Hashimoto C, Nomura W, Ohya A, Urano E, Miyauchi K, Narumi T, Aikawa H, Komano JA, Yamamoto N, Tamamura H: Evaluation of a synthetic C34 trimer of HIV-1 gp41 as AIDS vaccines. Bioorg Med Chem. 2012.05; 20 (10): 3287-3291. ( PubMed , DOI )

  5. Narumi T, Komoriya M, Hashimoto C, Wu H, Nomura W, Suzuki S, Tanaka T, Chiba J, Yamamoto N, Murakami T, Tamamura H: Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins. Bioorg Med Chem. 2012.02; 20 (4): 1468-1474. ( PubMed , DOI )

  6. Nomura W, Hashimoto C, Ohya A, Miyauchi K, Urano E, Tanaka T, Narumi T, Nakahara T, Komano JA, Yamamoto N, Tamamura H: A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency. ChemMedChem. 2012.02; 7 (2): 205-208. ( PubMed , DOI )

  7. Nomura W, Masuda A, Ohba K, Urabe A, Ito N, Ryo A, Yamamoto N, Tamamura H: Effects of DNA binding of the zinc finger and linkers for domain fusion on the catalytic activity of sequence-specific chimeric recombinases determined by a facile fluorescent system. Biochemistry. 2012.02; 51 (7): 1510-1517. ( PubMed , DOI )

  8. Tetsuo Narumi, Takuya Kobayakawa, Haruo Aikawa, Shunsuke Seike & Hirokazu Tamamura: Stereoselective Formation of Trisubstituted (Z)-Chloroalkenes Adjacent to a Tertiary Carbon Stereogenic Center by Organocuprate-Mediated Reduction/Alkylation. Org. Lett., 14(17), 4490-4493. 2012; 14 (17): 4490-4493.

  1. Narumi T, Arai H, Yoshimura K, Harada S, Nomura W, Matsushita S, Tamamura H: Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem. 2011.11; 19 (22): 6735-6742. ( PubMed , DOI )

  2. Hashimoto C, Tanaka T, Narumi T, Nomura W, Tamamura H: The successes and failures of HIV drug discovery. Expert Opin Drug Discov. 2011.10; 6 (10): 1067-1090. ( PubMed , DOI )

  3. Kohei Sato, Akira Shigenaga, Kohei Tsuji, Shugo Tsuda, Yoshitake Sumikawa, Ken Sakamoto, Akira Otaka: N-sulfanylethylanilide peptide as a crypto-thioester peptide. Chembiochem. 2011.08; 12 (12): 1840-1844. ( PubMed , DOI )

  4. Kohei Tsuji, Akira Shigenaga, Yoshitake Sumikawa, Kosuke Tanegashima, Kohei Sato, Keisuke Aihara, Takahiko Hara, Akira Otaka: Application of N-C- or C-N-directed sequential native chemical ligation to the preparation of CXCL14 analogs and their biological evaluation. Bioorg. Med. Chem.. 2011.07; 19 (13): 4014-4020. ( PubMed , DOI )

  5. Yamada M, Kubo H, Kobayashi S, Ishizawa K, He M, Suzuki T, Fujino N, Kunishima H, Hatta M, Nishimaki K, Aoyagi T, Tokuda K, Kitagawa M, Yano H, Tamamura H, Fujii N, Kaku M: The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury. Cell Mol Immunol. 2011.07; 8 (4): 305-314. ( PubMed , DOI )

  6. Xu C, Liu J, Chen L, Liang S, Fujii N, Tamamura H, Xiong H: HIV-1 gp120 enhances outward potassium current via CXCR4 and cAMP-dependent protein kinase A signaling in cultured rat microglia. Glia. 2011.06; 59 (6): 997-1007. ( PubMed , DOI )

  7. Nomura W, Ohashi N, Okuda Y, Narumi T, Ikura T, Ito N, Tamamura H: Fluorescence-quenching screening of protein kinase C ligands with an environmentally sensitive fluorophore. Bioconjug Chem. 2011.05; 22 (5): 923-930. ( PubMed , DOI )

  8. Tanaka T, Narumi T, Ozaki T, Sohma A, Ohashi N, Hashimoto C, Itotani K, Nomura W, Murakami T, Yamamoto N, Tamamura H: Azamacrocyclic metal complexes as CXCR4 antagonists. ChemMedChem. 2011.05; 6 (5): 834-839. ( PubMed , DOI )

  9. Nomura W, Narumi T, Ohashi N, Serizawa Y, Lewin NE, Blumberg PM, Furuta T, Tamamura H: Synthetic caged DAG-lactones for photochemically controlled activation of protein kinase C. Chembiochem. 2011.03; 12 (4): 535-539. ( PubMed , DOI )

  10. Tsutsumi H, Abe S, Mino T, Nomura W, Tamamura H: Intense blue fluorescence in a leucine zipper assembly. Chembiochem. 2011.03; 12 (5): 691-694. ( PubMed , DOI )

  11. Ohashi N, Nomura W, Narumi T, Lewin NE, Itotani K, Blumberg PM, Tamamura H: Fluorescent-responsive synthetic C1b domains of protein kinase Cdelta as reporters of specific high-affinity ligand binding. Bioconjug Chem. 2011.01; 22 (1): 82-87. ( PubMed , DOI )

  1. Tanaka T, Nomura W, Narumi T, Masuda A, Tamamura H: Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc. 2010.11; 132 (45): 15899-15901. ( PubMed , DOI )

  2. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, Ochiai C, Tamamura H, Matsushita S: Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol. 2010.08; 84 (15): 7558-7568. ( PubMed , DOI )

  3. Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H: Peptide HIV-1 Integrase Inhibitors from HIV-1 Gene Products. J Med Chem. 2010.07; 53 (14): 5356-5360. ( PubMed , DOI )

  4. Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H: Peptidic HIV integrase inhibitors derived from HIV gene products: Structure-activity relationship studies. Bioorg Med Chem. 2010.07; 18 6771-6775. ( PubMed , DOI )

  5. Melchionna R, Di Carlo A, De Mori R, Cappuzzello C, Barberi L, Musaro A, Cencioni C, Fujii N, Tamamura H, Crescenzi M, Capogrossi MC, Napolitano M, Germani A: Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors. Muscle Nerve. 2010.06; 41 (6): 828-835. ( PubMed , DOI )

  6. Nakahara T, Nomura W, Ohba K, Ohya A, Tanaka T, Hashimoto C, Narumi T, Murakami T, Yamamoto N, Tamamura H: Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies. Bioconjug Chem. 2010.04; 21 (4): 709-714. ( PubMed , DOI )

  7. Aoki T, Shimizu S, Urano E, Futahashi Y, Hamatake M, Tamamura H, Terashima K, Murakami T, Yamamoto N, Komano J: Improvement of lentiviral vector-mediated gene transduction by genetic engineering of the structural protein Pr55(Gag). Gene Ther. 2010.04; 17 (9): 1124-1133. ( PubMed , DOI )

  8. Yamada Y, Ochiai C, Yoshimura K, Tanaka T, Ohashi N, Narumi T, Nomura W, Harada S, Matsushita S, Tamamura H: CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett. 2010.01; 20 (1): 354-358. ( PubMed , DOI )

  9. Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, Nomura W, Arai H, Ozaki T, Ohashi N, Matsushita S, Tamamura H: CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett. 2010; 20 5853-5858. ( PubMed , DOI )

  10. Nomura W, Mino T, Narumi T, Ohashi N, Masuda A, Hashimoto C, Tsutsumi H, Tamamura H: Development of crosslink-type tag-probe pairs for fluorescent imaging of proteins. Biopolymers. 2010; 94 843-852. ( PubMed , DOI )

  1. Ohashi N, Nomura W, Kato M, Narumi T, Lewin NE, Blumberg PM, Tamamura H: Synthesis of protein kinase Cdelta C1b domain by native chemical ligation methodology and characterization of its folding and ligand binding. J Pept Sci. 2009.10; 15 (10): 642-646. ( PubMed , DOI )

  2. Tanaka T, Nomura W, Narumi T, Esaka A, Oishi S, Ohashi N, Itotani K, Evans BJ, Wang ZX, Peiper SC, Fujii N, Tamamura H: Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids. Org Biomol Chem. 2009.09; 7 (18): 3805-3809. ( PubMed , DOI )

  3. Inaba Y, Yoshimoto N, Sakamaki Y, Nakabayashi M, Ikura T, Tamamura H, Ito N, Shimizu M, Yamamoto K: A New Class of Vitamin D Analogues that Induce Structural Rearrangement of the Ligand-Binding Pocket of the Receptor. J Med Chem. 2009.02; ( PubMed , DOI )

  4. Mizukoshi F, Baba K, Goto-Koshino Y, Setoguchi-Mukai A, Fujino Y, Ohno K, Tamamura H, Oishi S, Fujii N, Tsujimoto H: Inhibitory effect of newly developed CXC-chemokine receptor 4 antagonists on the infection with feline immunodeficiency virus. J Vet Med Sci. 2009.01; 71 (1): 121-124. ( PubMed )

  5. Tsutsumi H, Nomura W, Abe S, Mino T, Masuda A, Ohashi N, Tanaka T, Ohba K, Yamamoto N, Akiyoshi K, Tamamura H: Fluorogenically active leucine zipper peptides as tag-probe pairs for protein imaging in living cells. Angew Chem Int Ed Engl. 2009; 48 (48): 9164-9166. ( PubMed , DOI )

  6. Tamamura H, Tanaka T, Tsutsumi H, Ohashi N, Hiramatsu K, Araki T, Ojida A, Hamachi I, Wang Z, Peiper SC, Trent JO, Ueda S, Oishi S, Fujii N: Development of chemokine receptor CXCR4 antagonists using bio-mimetic strategy. Adv Exp Med Biol. 2009; 611 145-146. ( PubMed )

  7. Tamamura H, Tanaka T, Tsutsumi H, Nemoto K, Mizokami S, Ohashi N, Oishi S, Fujii N: Stereoselective synthesis of peptidomimetics based on acid-catalyzed ring-opening of beta-aziridinyl-alpha,beta-enoates. Adv Exp Med Biol. 2009; 611 149-150. ( PubMed )

  1. Tanaka T, Tsutsumi H, Nomura W, Tanabe Y, Ohashi N, Esaka A, Ochiai C, Sato J, Itotani K, Murakami T, Ohba K, Yamamoto N, Fujii N, Tamamura H: Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore. Org Biomol Chem. 2008.12; 6 (23): 4374-4377. ( PubMed , DOI )

  2. Nomura W, Tanabe Y, Tsutsumi H, Tanaka T, Ohba K, Yamamoto N, Tamamura H: Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening. Bioconjug Chem. 2008.09; 19 (9): 1917-1920. ( PubMed , DOI )

  3. Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tamamura H, Fujii N, Mitsuya H: Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother. 2008.06; 52 (6): 2111-2119. ( PubMed , DOI )

  4. Driessen WH, Fujii N, Tamamura H, Sullivan SM: Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol Ther. 2008.03; 16 (3): 516-524. ( PubMed , DOI )

  5. Hirokazu Tamamura, Hiroshi Tsutsumi, Wataru Nomura, Tomohiro Tanaka & Nobutaka Fujii: A Future Perspective on the Development of Chemokine Receptor CXCR4 Antagonists. Expert Opin. Drug Discovery. 2008; 3 (10): 1150-1166.

  6. Kasiyanov A, Fujii N, Tamamura H, Xiong H: Modulation of network-driven, GABA-mediated giant depolarizing potentials by SDF-1alpha in the developing hippocampus. Dev Neurosci. 2008; 30 (4): 285-292. ( PubMed , DOI )

  7. Tamamura H, Tsutsumi H, Nomura W, Fujii N: Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing. Perspect Medicin Chem. 2008; 2 1-9. ( PubMed )

  1. Kabashima K, Sugita K, Shiraishi N, Tamamura H, Fujii N, Tokura Y: CXCR4 engagement promotes dendritic cell survival and maturation. Biochem Biophys Res Commun. 2007.10; 361 (4): 1012-1016. ( PubMed , DOI )

  2. Kabashima K, Shiraishi N, Sugita K, Mori T, Onoue A, Kobayashi M, Sakabe J, Yoshiki R, Tamamura H, Fujii N, Inaba K, Tokura Y: CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol. 2007.10; 171 (4): 1249-1257. ( PubMed , DOI )

  3. Kubonishi S, Kikuchi T, Yamaguchi S, Tamamura H, Fujii N, Watanabe T, Arenzana-Seisdedos F, Ikeda K, Matsui T, Tanimoto M, Katayama Y: Rapid hematopoietic progenitor mobilization by sulfated colominic acid. Biochem Biophys Res Commun. 2007.04; 355 (4): 970-975. ( PubMed , DOI )

  4. Berchiche YA, Chow KY, Lagane B, Leduc M, Percherancier Y, Fujii N, Tamamura H, Bachelerie F, Heveker N: Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G(alpha)(i) activation. J Biol Chem. 2007.02; 282 (8): 5111-5115. ( PubMed , DOI )

  5. Ueda S, Oishi S, Wang ZX, Araki T, Tamamura H, Cluzeau J, Ohno H, Kusano S, Nakashima H, Trent JO, Peiper SC, Fujii N: Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem. 2007.01; 50 (2): 192-198. ( PubMed , DOI )

  6. Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, Araki T, Ueda S, Oishi S, Fujii N: Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers. 2007; 88 (2): 279-289. ( PubMed , DOI )

  7. Tamamura H, Tsutsumi H, Masuno H, Fujii N: Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr Med Chem. 2007; 14 (1): 93-102. ( PubMed )

  8. Hiroshi Tsutsumi, Hirokazu Tamamura & Nobutaka Fujii: Inhibitors of the Chemokine Receptor CXCR4. Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis. Lett. Drug Design Discovery. 2007; 4 20-26.

  9. Hirokazu Tamamura, Tomohiro Tanaka, Hiroshi Tsutsumi, Koji Nemoto, Satoko Mizokami, Nami Ohashi, Shinya Oishi & Nobutaka Fujii: Versatile Use of Acid-catalyzed Ring-opening of β-Aziridinyl-α,β-enoates to Stereoselective Synthesis of Peptidomimetics. Tetrahedron. 2007; 63 9243-9254.

  1. Tamamura H, Tsutsumi H, Fujii N: The chemokine receptor CXCR4 as a therapeutic target for several diseases. Mini Rev Med Chem. 2006.09; 6 (9): 989-995. ( PubMed )

  2. Tamamura H, Tsutsumi H, Masuno H, Mizokami S, Hiramatsu K, Wang Z, Trent JO, Nakashima H, Yamamoto N, Peiper SC, Fujii N: Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org Biomol Chem. 2006.06; 4 (12): 2354-2357. ( PubMed , DOI )

  3. Tamamura H, Ojida A, Ogawa T, Tsutsumi H, Masuno H, Nakashima H, Yamamoto N, Hamachi I, Fujii N: Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J Med Chem. 2006.06; 49 (11): 3412-3415. ( PubMed , DOI )

  4. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K: The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica. 2006.05; 91 (5): 605-612. ( PubMed )

  5. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H: Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006.05; 33 (4): 489-494. ( PubMed , DOI )

  6. Niida A, Tanigaki H, Inokuchi E, Sasaki Y, Oishi S, Ohno H, Tamamura H, Wang Z, Peiper SC, Kitaura K, Otaka A, Fujii N: Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and their use in the preparation of low-molecule CXCR4 antagonists. J Org Chem. 2006.05; 71 (10): 3942-3951. ( PubMed , DOI )

  7. Kasyanov A, Tamamura H, Fujii N, Xiong H: HIV-1 gp120 enhances giant depolarizing potentials via chemokine receptor CXCR4 in neonatal rat hippocampus. Eur J Neurosci. 2006.03; 23 (5): 1120-1128. ( PubMed , DOI )

  8. Tamamura H, Tsutsumi H: Specific probes for chemokine receptors. Chem Biol. 2006.01; 13 (1): 8-10. ( PubMed , DOI )

  9. Niida A, Wang Z, Tomita K, Oishi S, Tamamura H, Otaka A, Navenot JM, Broach JR, Peiper SC, Fujii N: Design and synthesis of downsized metastin (45-54) analogs with maintenance of high GPR54 agonistic activity. Bioorg Med Chem Lett. 2006.01; 16 (1): 134-137. ( PubMed , DOI )

  10. Shinya Oishi, Kazuhide Miyamoto, Ayumu Niida, Mikio Yamamoto, Keiichi Ajito, Hirokazu Tamamura, Akira Otaka, Yoshihiro Kuroda, Akira Asai & Nobutaka Fujii: Application of Tri- and Tetrasubstituted Alkene Dipeptide Mimetics to Conformational Studies of Cyclic RGD Peptides. Tetrahedron. 2006; 62 1416-1424.

  11. Hirokazu Tamamura & Hiroshi Tsutsumi: Specific Probes for Chemokine Receptors Chem. Biol.. 2006; 13 8-10.

  1. Tamamura H, Esaka A, Ogawa T, Araki T, Ueda S, Wang Z, Trent JO, Tsutsumi H, Masuno H, Nakashima H, Yamamoto N, Peiper SC, Otaka A, Fujii N: Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org Biomol Chem. 2005.12; 3 (24): 4392-4394. ( PubMed , DOI )

  2. Tamamura H, Fujii N: The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets. 2005.12; 9 (6): 1267-1282. ( PubMed , DOI )

  3. Ueda S, Fujita M, Tamamura H, Fujii N, Otaka A: Photolabile protection for one-pot sequential native chemical ligation. Chembiochem. 2005.11; 6 (11): 1983-1986. ( PubMed , DOI )

  4. Tamamura H, Otaka A, Fujii N: Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides. Curr HIV Res. 2005.10; 3 (4): 289-301. ( PubMed )

  5. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA: Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005.09; 106 (5): 1824-1830. ( PubMed , DOI )

  6. Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, Trent JO, Nakashima H, Yamamoto N, Peiper SC, Otaka A, Fujii N: Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem. 2005.05; 48 (9): 3280-3289. ( PubMed , DOI )

  7. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, Bouvier M, Heveker N: Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem. 2005.03; 280 (11): 9895-9903. ( PubMed , DOI )

  8. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S: Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005.03; 65 (5): 1700-1709. ( PubMed , DOI )

  9. Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L, Zamarchi R, Tamamura H, Fujii N, Semenzato G, Chieco-Bianchi L, Amadori A: Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood. 2005.02; 105 (3): 931-939. ( PubMed , DOI )

  10. Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M: Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol. 2005.01; 79 (2): 764-770. ( PubMed , DOI )

  11. Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, Terakubo S, Trent JO, Peiper SC, Yamamoto N, Nakashima H, Otaka A, Fujii N: Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005.01; 48 (2): 380-391. ( PubMed , DOI )

  12. Ayumu Niida, Shinya Oishi, Yoshikazu Sasaki, Makiko Mizumoto, Hirokazu Tamamura, Nobutaka Fujii & Akira Otaka: Facile Access to (Z)-Alkene-containing Diketopiperazine Mimetics Utilizing Organocopper-mediated Anti-SN2' Reactions. Tetrahedron Lett.. 2005; 46 4183-4186.

  13. Margitta Retz, Sachdev S. Sidhu, Jan Lehmann, Hirokazu Tamamura, Nobutaka Fujii & Carol Basbaum: New HIV-Drug Inhibits in Vitro Bladder Cancer Migration and Invasion Eur. Urol.. 2005; 48 (6): 1025-1030.

  14. Jayendra B. Bhonsle, Zi-xuan Wang, Hirokazu Tamamura, Nobutaka Fujii, Stephen C. Peiper & John O. Trent: A Simple, Automated Quasi-4D-QSAR, Quasi-multi Way PLS Approach to Develop Highly Predictive QSAR Models for Highly Flexible CXCR4 Inhibitor Cyclic Peptide Ligands Using Scripted Common Molecular Modeling Tools. QSAR Comb. Sci.. 2005; 24 (5): 620-630.

  1. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N, Cyster JG: Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004.09; 5 (9): 943-952. ( PubMed , DOI )

  2. Tamamura H, Sigano DM, Lewin NE, Peach ML, Nicklaus MC, Blumberg PM, Marquez VE: Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C). J Med Chem. 2004.09; 47 (20): 4858-4864. ( PubMed , DOI )

  3. Otaka A, Ueda S, Tomita K, Yano Y, Tamamura H, Matsuzaki K, Fujii N: Facile synthesis of membrane-embedded peptides utilizing lipid bilayer-assisted chemical ligation. Chem Commun (Camb). 2004.08; (15): 1722-1723. ( PubMed , DOI )

  4. Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N: Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett. 2004.07; 569 (1-3): 99-104. ( PubMed , DOI )

  5. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N: HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004.06; 318 (3): 719-725. ( PubMed , DOI )

  6. Tamamura H, Fujii N: Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists. Curr Drug Targets Infect Disord. 2004.06; 4 (2): 103-110. ( PubMed )

  7. Peng H, Huang Y, Rose J, Erichsen D, Herek S, Fujii N, Tamamura H, Zheng J: Stromal cell-derived factor 1-mediated CXCR4 signaling in rat and human cortical neural progenitor cells. J Neurosci Res. 2004.04; 76 (1): 35-50. ( PubMed , DOI )

  8. Tamamura H, Mizumoto M, Hiramatsu K, Kusano S, Terakubo S, Yamamoto N, Trent JO, Wang Z, Peiper SC, Nakashima H, Otaka A, Fujii N: Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org Biomol Chem. 2004.04; 2 (8): 1255-1257. ( PubMed , DOI )

  9. Otaka A, Watanabe J, Yukimasa A, Sasaki Y, Watanabe H, Kinoshita T, Oishi S, Tamamura H, Fujii N: SmI2-mediated reduction of gamma,gamma-difluoro-alpha,beta-enoates with application to the synthesis of functionalized (Z)-fluoroalkene-type dipeptide isosteres. J Org Chem. 2004.03; 69 (5): 1634-1645. ( PubMed , DOI )

  10. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K, Fujii N, Imamura M: CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004.01; 3 (1): 29-37. ( PubMed )

  11. Tamamura H, Sigano DM, Lewin NE, Blumberg PM, Marquez VE: Conformationally constrained analogues of diacylglycerol. 20. The search for an elusive binding site on protein kinase C through relocation of the carbonyl pharmacophore along the sn-1 side chain of 1,2-diacylglycerol lactones. J Med Chem. 2004.01; 47 (3): 644-655. ( PubMed , DOI )

  12. Mitsuko Takenaga, Hirokazu Tamamura, Kenichi Hiramatsu, Natsumi Nakamura, Yoko Yamaguchi, Aki Kitagawa, Shinichi Kawai, Hideki Nakashima, Nobutaka Fujii & Rie Igarashi: A Single Treatment with Microcapsules Containing a CXCR4 Antagonist Suppresses Pulmonary Metastasis of Murine Melanoma. Biochem. Biophys. Res. Commun.. 2004; 320 (1): 226-232.

  1. Trent JO, Wang ZX, Murray JL, Shao W, Tamamura H, Fujii N, Peiper SC: Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem. 2003.11; 278 (47): 47136-47144. ( PubMed , DOI )

  2. Tamamura H, Hiramatsu K, Mizumoto M, Ueda S, Kusano S, Terakubo S, Akamatsu M, Yamamoto N, Trent JO, Wang Z, Peiper SC, Nakashima H, Otaka A, Fujii N: Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem. 2003.11; 1 (21): 3663-3669. ( PubMed )

  3. Tamamura H, Hiramatsu K, Kusano S, Terakubo S, Yamamoto N, Trent JO, Wang Z, Peiper SC, Nakashima H, Otaka A, Fujii N: Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org Biomol Chem. 2003.11; 1 (21): 3656-3662. ( PubMed )

  4. Oonuma T, Morimatsu M, Nakagawa T, Uyama R, Sasaki N, Nakaichi M, Tamamura H, Fujii N, Hashimoto S, Yamamura H, Syuto B: Role of CXCR4 and SDF-1 in mammary tumor metastasis in the cat. J Vet Med Sci. 2003.10; 65 (10): 1069-1073. ( PubMed )

  5. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N: T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003.08; 550 (1-3): 79-83. ( PubMed )

  6. Otaka A, Yukimasa A, Watanabe J, Sasaki Y, Oishi S, Tamamura H, Fujii N: Application of samarium diiodide (SmI2)-induced reduction of gamma-acetoxy-alpha,beta-enoates with alpha-specific kinetic electrophilic trapping for the synthesis of amino acid derivatives. Chem Commun (Camb). 2003.08; (15): 1834-1835. ( PubMed )

  7. Tamamura H, Kato T, Otaka A, Fujii N: Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org Biomol Chem. 2003.07; 1 (14): 2468-2473. ( PubMed )

  8. Fujii N, Oishi S, Hiramatsu K, Araki T, Ueda S, Tamamura H, Otaka A, Kusano S, Terakubo S, Nakashima H, Broach JA, Trent JO, Wang ZX, Peiper SC: Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Ed Engl. 2003.07; 42 (28): 3251-3253. ( PubMed , DOI )

  9. Yasuda T, Poole AR, Shimizu M, Nakagawa T, Julovi SM, Tamamura H, Fujii N, Nakamura T: Involvement of CD44 in induction of matrix metalloproteinases by a COOH-terminal heparin-binding fragment of fibronectin in human articular cartilage in culture. Arthritis Rheum. 2003.05; 48 (5): 1271-1280. ( PubMed , DOI )

  10. Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, Maeda K, Watai Y, Arikuni H, Otaka A, Mitsuya H, Fujii N: Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains. J Med Chem. 2003.04; 46 (9): 1764-1768. ( PubMed , DOI )

  11. Fujii N, Nakashima H, Tamamura H: The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs. 2003.02; 12 (2): 185-195. ( PubMed , DOI )

  1. Oishi S, Kamano T, Niida A, Odagaki Y, Hamanaka N, Yamamoto M, Ajito K, Tamamura H, Otaka A, Fujii N: Diastereoselective synthesis of new psi[(E)-CH=CMe]- and psi[(Z)-CH=CMe]-type alkene dipeptide isosteres by organocopper reagents and application to conformationally restricted cyclic RGD peptidomimetics. J Org Chem. 2002.08; 67 (17): 6162-6173. ( PubMed )

  2. Otaka A, Nakamura M, Nameki D, Kodama E, Uchiyama S, Nakamura S, Nakano H, Tamamura H, Kobayashi Y, Matsuoka M, Fujii N: Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl. 2002.08; 41 (16): 2937-2940. ( PubMed , DOI )

  3. Otaka A, Katagiri F, Kinoshita T, Odagaki Y, Oishi S, Tamamura H, Hamanaka N, Fujii N: Regio- and stereoselective synthesis of (E)-alkene trans-Xaa-Pro dipeptide mimetics utilizing organocopper-mediated anti-S(N)2' reactions. J Org Chem. 2002.08; 67 (17): 6152-6161. ( PubMed )

  4. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, Peiper SC: A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 2002.07; 277 (27): 24515-24521. ( PubMed , DOI )

  5. Tamamura H, Omagari A, Hiramatsu K, Oishi S, Habashita H, Kanamoto T, Gotoh K, Yamamoto N, Nakashima H, Otaka A, Fujii N: Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study. Bioorg Med Chem. 2002.05; 10 (5): 1417-1426. ( PubMed )

  6. Oishi S, Kamano T, Niida A, Odagaki Y, Tamamura H, Otaka A, Hamanaka N, Fujii N: Diastereoselective synthesis of psi[(E)-CH=CMe]- and psi[(Z)-CH=CMe]-type dipeptide isosteres by organocopper-mediated anti-S(N)2' reaction. Org Lett. 2002.04; 4 (7): 1051-1054. ( PubMed )

  7. Oishi S, Niida A, Kamano T, Odagaki Y, Tamamura H, Otaka A, Hamanaka N, Fujii N: Diastereoselective synthesis of psi[(E)-CMe=CH]- and psi[(E)-CMe=CMe]- type dipeptide isosteres based on organocopper-mediated anti-S(N)2' reaction. Org Lett. 2002.04; 4 (7): 1055-1058. ( PubMed )

  8. Tamamura H, Hiramatsu K, Miyamoto K, Omagari A, Oishi S, Nakashima H, Yamamoto N, Kuroda Y, Nakagawa T, Otaka A, Fujii N: Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety. Bioorg Med Chem Lett. 2002.03; 12 (6): 923-928. ( PubMed )

  9. Shinya Oishi, Ayumu Niida, Takae Kamano, Yoshihisa Miwa, Tooru Taga, Yoshihiko Odagaki, Nobuyuki Hamanaka, Mikio Yamamoto, Keiichi Ajito, Hirokazu Tamamura, Akira Otaka & Nobutaka Fujii: Regio- and Stereoselective Ring-opening of Chiral 1,3-Oxazolidin-2-one Derivatives by Organocopper Reagents Provides Novel Access to Di-, tri- and tetra-substituted Alkene Dipeptide Isosteres. J. Chem. Soc., Perkin Trans.. 2002; 1 (2002(15)): 1786-1793.

  10. Hirokazu Tamamura, Tadakazu Hori, Akira Otaka & Nobutaka Fujii: Efficient Stereoselective Synthesis of Peptidomimetics Containing Hydroxyethylamine Dipeptide Isosteres Utilizing the Aza-Payne Rearrangement and O, N-Acyl Transfer Reactions. J. Chem. Soc., Perkin Trans.. 2002; 1 (2002(5)): 577-580.

  1. Tamamura H: [Development of selective antagonists against an HIV second receptor] Yakugaku Zasshi. 2001.11; 121 (11): 781-792. ( PubMed )

  2. Fujii N, Tamamura H: Peptide-lead CXCR4 antagonists with high anti-HIV activity. Curr Opin Investig Drugs. 2001.09; 2 (9): 1198-1202. ( PubMed )

  3. Tamamura H, Omagari A, Hiramatsu K, Kanamoto T, Gotoh K, Kanbara K, Yamamoto N, Nakashima H, Otaka A, Fujii N: Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorg Med Chem. 2001.08; 9 (8): 2179-2187. ( PubMed )

  4. Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, Kodama E, Matsuoka M, Hattori T, Yamamoto N, Nakashima H, Otaka A, Fujii N: Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001.07; 11 (14): 1897-1902. ( PubMed )

  5. Gotoh K, Yoshimori M, Kanbara K, Tamamura H, Kanamoto T, Mochizuki K, Fujii N, Nakashima H: Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1. J Infect Chemother. 2001.03; 7 (1): 28-36. ( PubMed , DOI )

  6. Tamamura H, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, Nakashima H, Yamamoto N, Peiper SC, Hamanaka N, Otaka A, Fujii N: Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg Med Chem Lett. 2001.02; 11 (3): 359-362. ( PubMed )

  7. Kenji Kanbara, Setsuko Sato, Jun-ichi Tanuma, Hirokazu Tamamura, Kazuyo Gotoh, Manabu Yoshimori, Taisei Kanamoto, Motoo Kitano, Nobutaka Fujii & Hideki Nakashima: Biological and Genetic Characterization of a Human Immunodeficiency Virus Strain Resistant to CXCR4 Antagonist T134. AIDS Res. Hum. Retroviruses. 2001; 17 (7): 615-622.

  8. Shinya Oishi, Hirokazu Tamamura, Masaki Yamashita, Yoshihiko Odagaki, Nobuyuki Hamanaka, Akira Otaka & Nobutaka Fujii: Stereoselective Synthesis of a Set of Two Functionalized (E)-Alkene Dipeptide Isosteres of L-Amino Acid-L-Glu and L-Amino acid-D-Glu. J. Chem. Soc., Perkin Trans.. 2001; 1 (19): 2445-2451.

  9. Akira Otaka, Hideaki Watanabe, Akira Yukimasa, Shinya Oishi, Hirokazu Tamamura & Nobutaka Fujii: New Access to α-Substituted (Z)-Fluoroalkene Dipeptide Isosteres Utilizing Organocopper Reagents under 'Reduction-oxidative Alkylation (R-OA)' Conditions. Tetrahedron Lett.. 2001; 42 (2): 5443-5446.

  10. 玉村　啓和: HIV侵入の第二受容体に対する特異的拮抗剤の発見と応用に関する研究 薬学雑誌. 2001; 121 (11): 781-792.

  1. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Otaka A, Fujii N: Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett. 2000.12; 10 (23): 2633-2637. ( PubMed )

  2. Miyoshi K, Otaka A, Kaneko M, Tamamura H, Fujii N: A new practical strategy for the synthesis of long-chain phosphopeptide. Chem Pharm Bull (Tokyo). 2000.08; 48 (8): 1230-1233. ( PubMed )

  3. Otaka A, Mitsuyama E, Kinoshita T, Tamamura H, Fujii N: Stereoselective synthesis of CF(2)-substituted phosphothreonine mimetics and their incorporation into peptides using newly developed deprotection procedures. J Org Chem. 2000.08; 65 (16): 4888-4899. ( PubMed )

  4. Tamamura H, Bienfait B, Nacro K, Lewin NE, Blumberg PM, Marquez VE: Conformationally constrained analogues of diacylglycerol (DAG). 17. Contrast between sn-1 and sn-2 DAG lactones in binding to protein kinase C. J Med Chem. 2000.08; 43 (17): 3209-3217. ( PubMed )

  5. Udaka K, Wiesmuller KH, Kienle S, Jung G, Tamamura H, Yamagishi H, Okumura K, Walden P, Suto T, Kawasaki T: An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. Immunogenetics. 2000.08; 51 (10): 816-828. ( PubMed )

  6. Akira Otaka, Etsuko Mitsuyama, Hideaki Watanabe, Hirokazu Tamamura & Nobutaka Fujii: Development of New Methodology for the Synthesis of Functionalized α-Fluorophosphonates and Its Practical Application to the Preparation of Phosphopeptide Mimetics. Chem. Commun.. 2000; 1081-1082.

  7. Kakugawa K, Udaka K, Nakashima K, Inaba K, Oka Y, Sugiyama H, Tamamura H, Yamagishi H: Efficient induction of peptide-specific cytotoxic T lymphocytes by LPS-activated spleen cells. Microbiol Immunol. 2000; 44 (2): 123-133. ( PubMed )

  1. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol. 1999.09; 73 (9): 7489-7496. ( PubMed )

  2. Xu Y, Tamamura H, Arakaki R, Nakashima H, Zhang X, Fujii N, Uchiyama T, Hattori T: Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res Hum Retroviruses. 1999.03; 15 (5): 419-427. ( PubMed , DOI )

  3. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, Nakashima H: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol. 1999.02; 73 (2): 1719-1723. ( PubMed )

  4. Hirokazu Tamamura, Masaki Yamashita, Yutaka Nakajima, Kyoko Sakano, Akira Otaka, Hiroaki Ohno, Toshiro Ibuka & Nobutaka Fujii: Regiospecific Ring-Opening Reactions of β-Aziridinyl α,β-Enoates with Acids: Application to the Stereoselective Synthesis of a Couple of Diastereoisomeric (E)-Alkene Dipeptide Isosteres from a Single β-Aziridinyl α,β-Enoate and to the Convenient Preparation of Amino Alcohols Bearing α,β-Unsaturated Ester Groups. J. Chem. Soc., Perkin Trans.. 1999; 1 2983-2996.

  1. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N: A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998.12; 253 (3): 877-882. ( PubMed , DOI )

  2. Hattori T, Komoda H, Pahwa S, Tateyama M, Zhang X, Xu Y, Oguma S, Tamamura H, Fujii N, Fukutake K, Uchiyama T: Decline of anti-DP107 antibody associated with clinical progression. AIDS. 1998.08; 12 (12): 1557-1559. ( PubMed )

  3. Tamamura H, Imai M, Ishihara T, Masuda M, Funakoshi H, Oyake H, Murakami T, Arakaki R, Nakashima H, Otaka A, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N: Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem. 1998.07; 6 (7): 1033-1041. ( PubMed )

  4. Oguchi M, Higashi K, Taniguchi M, Nishikawa T, Tamamura H, Okimura T, Yamamoto I: Single photon emission CT images in a case of intraventricular neurocytoma. Ann Nucl Med. 1998.06; 12 (3): 161-164. ( PubMed )

  5. Tamamura H, Waki M, Imai M, Otaka A, Ibuka T, Waki K, Miyamoto K, Matsumoto A, Murakami T, Nakashima H, Yamamoto N, Fujii N: Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. Bioorg Med Chem. 1998.04; 6 (4): 473-479. ( PubMed )

  6. Tamamura H, Arakaki R, Funakoshi H, Imai M, Otaka A, Ibuka T, Nakashima H, Murakami T, Waki M, Matsumoto A, Yamamoto N, Fujii N: Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II). Bioorg Med Chem. 1998.02; 6 (2): 231-238. ( PubMed )

  7. Hirokazu Tamamura, Tsunehito Ishihara, Hiromi Oyake, Makoto Imai, Akira Otaka, Toshiro Ibuka, Rieko Arakaki, Hideki Nakashima, Tsutomu Murakami, Michinori Waki, Akiyoshi Matsumoto, Naoki Yamamoto & Nobutaka Fujii: Convenient One-pot Synthesis of Cystine-Containing Peptides Using the Trimethylsilyl Chloride-Dimethylsulfoxide/Trifluoroacetic Acid System and its Application to the Synthesis of Bifunctional Anti-HIV Compounds. J. Chem. Soc., Perkin Trans.. 1998; 1 (3): 495-500.

  8. Hiroaki Ohno, Kiyonori Ishii, Asami Honda, Hirokazu Tamamura, Nobutaka Fujii, Yoshiji Takemoto & Toshiro Ibuka: A 2,3-cis-Selective Synthesis of Aziridines Bearing a Vinyl Group from Allyl Methyl Carbonates and Allyl Mesylates. J. Chem. Soc., Perkin Trans.. 1998; 1 (22): 3703-3716.

  9. Uenishi H, Iwanami N, Yamagishi H, Nakatani T, Kawasaki T, Tamamura H, Fujii N, Kuribayashi K: Induction of cross-reactivity in an endogenous viral peptide non-reactive to FBL-3 tumor-specific helper T-cell clones. Microbiol Immunol. 1998; 42 (7): 479-484. ( PubMed )

  10. 玉村　啓和・藤井　信孝: Coreceptorを標的とした抗エイズ薬剤の開発状況 日本ME学会雑誌BioMedical Engineering. 1998; 12 (10): 44-51.

  1. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 1997.10; 186 (8): 1389-1393. ( PubMed )

  2. Ibuka T, Mimura N, Ohno H, Nakai K, Akaji M, Habashita H, Tamamura H, Miwa Y, Taga T, Fujii N, Yamamoto Y: Palladium(0)-Catalyzed Isomerization Reactions of Aziridines Bearing an alpha,beta-Unsaturated Ester Group: A Thermodynamic Preference for Chiral Alkyl (2E)-4,5-cis-4,5-Epimino-N-(alkyl- or arylsulfonyl) 2-Enoates over the Other Three Stereoisomers. J Org Chem. 1997.05; 62 (9): 2982-2991. ( PubMed )

  3. Hiroshi Aoyama, Norio Mimura, Hiroaki Ohno, Kiyonori Ishii, Ayako Toda, Hirokazu Tamamura, Akira Otaka, Nobutaka Fujii & Toshiro Ibuka: Regio- and Stereoselectivity in Reactions of 2,3-cis- and trans-3-Alkyl-2-vinylaziridines with Organocopper Reagents: Importance of 2,3-cis-Stereochemistry in Controlling Selectivity. Tetrahedron Lett.. 1997; 38 (42): 7383-7386.

  4. Hiroaki Ohno, Norio Mimura, Akira Otaka, Hirokazu Tamamura, Nobutaka Fujii, Toshiro Ibuka, Isao Shimizu, Akiharu Satake & Yoshinori Yamamoto: Palladium-Catalyzed Reductive Ring Opening with Formic Acid of Aziridines Bearing an α, β-Unsaturated Ester Group. Tetrahedron. 1997; 53 (38): 12933-12946.

  5. Toshiro Ibuka, Norio Mimura, Hiroshi Aoyama, Masako Akaji, Hiroaki Ohno, Yoshihisa Miwa, Tooru Taga, Kazuo Nakai, Hirokazu Tamamura, Nobutaka Fujii & Yoshinori Yamamoto: A Thermodynamic Preference of Chiral N-Methanesulfonyl and N-Arenesulfonyl 2,3-cis-3-Alkyl-2-vinylaziridines over Their 2,3-trans-Isomers: Useful Palladium(0)-Catalyzed Equilibration Reactions for the Synthesis of (E)-Alkene Dipeptide Isosters. J. Org. Chem.. 1997; 62 (4): 999-1015.

  6. Hiromu Habashita, Takeshi Kawasaki, Masako Akaji, Hirokazu Tamamura, Tetsutaro Kimachi, Nobutaka Fujii & Toshiro Ibuka: One-Pot Transformation of p-Toluenesulfonates of 2,3-Epoxy Alcohols into Allylic Alcohols. Tetrahedron Lett.. 1997; 38 (48): 8307-8310.

  1. Tamamura H, Otaka A, Murakami T, Ibuka T, Sakano K, Waki M, Matsumoto A, Yamamoto N, Fujii N: An anti-HIV peptide, T22, forms a highly active complex with Zn(II). Biochem Biophys Res Commun. 1996.12; 229 (2): 648-652. ( PubMed , DOI )

  2. Tamamura H, Ishihara T, Otaka A, Murakami T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N: Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance. Biochim Biophys Acta. 1996.11; 1298 (1): 37-44. ( PubMed )

  3. Tamamura H, Otaka A, Murakami T, Ishihara T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N: Interaction of an anti-HIV peptide, T22, with gp120 and CD4. Biochem Biophys Res Commun. 1996.02; 219 (2): 555-559. ( PubMed , DOI )

  4. Toshiro Ibuka, Masako Akaji, Norio Mimura, Hiromu Habashita, Kazuo Nakai, Hirokazu Tamamura, Nobutaka Fujii & Yoshinori Yamamoto: A Thermodynamic Preference of Chiral cis-γ,δ-Epimino-(E)-α,β-Unsaturated Esters over Other Stereoisomers: Synthetically Useful Pd(0)-Catalyzed Equilibrated Reactions of Aziridines Bearing an α,β-Unsaturated Ester Groups. Tetrahedron Lett.,. 1996; 37 2849-2852.

  5. Toshiro Ibuka, Kazuo Nakai, Masako Akaji, Hirokazu Tamamura, Nobutaka Fujii & Yoshinori Yamamoto: An Aza-Payne Rearrangement-Epoxide Ring Opening Reaction of 2-Aziridinemethanols in a One-pot Manner: A Regio- and Stereoselective Synthetic Route to Diastereomerically Pure N-Protected 1,2-Amino Alcohols. Tetrahedron. 1996; 52 11739-11752.

  6. Norio Mimura, Toshiro Ibuka, Masako Akaji, Yoshihisa Miwa, Tooru Taga, Kazuo Nakai, Hirokazu Tamamura, Nobutaka Fujii & Yoshinori Yamamoto: An Unusual Thermodynamic Preference of Chiral N-Arylsulfonyl cis-3-Alkyl-2-vinylaziridines over Their trans-Isomers: Palladium(0)-Catalyzed Equilibration Reaction. J. Chem. Soc., Chem. Commun.. 1996; 351-352.

  7. Nobutaka Fujii, Hiromu Habashita, Masako Akaji, Kazuo Nakai, Toshiro Ibuka, Masahiro Fujiwara, Hirokazu Tamamura & Yoshinori Yamamoto: A Simple One-pot Transformation of p-Toluenesulfonates of 2,3-Epoxy Alcohols into Allylic Alcohols. J. Chem. Soc., Perkin Trans. (Perkin Commun.). 1996; 1 1996, 865-866.

  8. Michinori Waki, Koji Waki, Kenji Miyamoto, Akiyoshi Matsumoto, Hirokazu Tamamura, Nobutaka Fujii, Tsutomu Murakami, Hideki Nakashima & Naoki Yamamoto: Molecular Size of an Anti-HIV Peptide, T22, Can Be Reduced without Loss of the Activity. Chem. Lett.. 1996; 571-572.

  9. Hirokazu Tamamura, Tsunehito Ishihara, Akira Otaka, Takaki Koide, Kengo Miyoshi, Toshiro Ibuka & Nobutaka Fujii: A Convenient One-pot Synthesis of Cystine-Containing Peptides from Protected Peptidyl Resins Using the Trimethylsilyl Chloride-Dimethylsulfoxide-Trifluoroacetic Acid System. J. Chem. Soc., Perkin Trans. (Perkin Commun.). 1996; 1 1911-1912.

  1. Kondo T, Uenishi H, Shimizu T, Hirama T, Iwashiro M, Kuribayashi K, Tamamura H, Fujii N, Fujisawa R, Miyazawa M, et al.: A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J Virol. 1995.11; 69 (11): 6735-6741. ( PubMed )

  2. Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Yamamoto N, Fujii N: The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Biochem Biophys Res Commun. 1995.10; 215 (2): 626-631. ( PubMed , DOI )

  3. Tamamura H, Murakami T, Horiuchi S, Sugihara K, Otaka A, Takada W, Ibuka T, Waki M, Yamamoto N, Fujii N: Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Chem Pharm Bull (Tokyo). 1995.05; 43 (5): 853-858. ( PubMed )

  4. Tamamura H, Otaka A, Nakamura J, Okubo K, Koide T, Ikeda K, Ibuka T, Fujii N: Disulfide bond-forming reaction using a dimethyl sulfoxide/aqueous HCl system and its application to regioselective two disulfide bond formation. Int J Pept Protein Res. 1995.04; 45 (4): 312-319. ( PubMed )

  5. Tamamura H, Otaka A, Takada W, Terakawa Y, Yoshizawa H, Masuda M, Ibuka T, Murakami T, Nakashima H, Waki M, et al.: Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection. Chem Pharm Bull (Tokyo). 1995.01; 43 (1): 12-18. ( PubMed )

  6. Nobutaka Fujii, Kazuo Nakai, Hirokazu Tamamura, Akira Otaka, Norio Mimura, Yoshihisa Miwa, Tooru Taga, Yoshinori Yamamoto & Toshiro Ibuka: SN2' Ring Opening of Aziridines Bearing an α,β-Unsaturated Ester Group with Organocopper Reagents. A New Stereoselective Synthesis Route to (E)-Alkene Dipeptide Isosters. J. Chem. Soc., Perkin Trans.. 1995; 1 1359-1371.

  7. Akira Otaka, Kengo Miyoshi, Terrence R. Burke, Jr., Peter P. Roller, Hideki Kubota, Hirokazu Tamamura & Nobutaka Fujii: Synthesis and Application of N-Boc-L-2-amino-4-(diethylphosphono)-4, 4-difluorobutanoic acid for Solid-Phase Synthesis of Nonhydrolyzable Phosphoserine Peptide Analogs. Tetrahedron Lett.. 1995; 36 927-930.

  8. Akira Otaka, Kengo Miyoshi, Midori Kaneko, Hirokazu Tamamura, Nobutaka Fujii, Motoyoshi Nomizu, Terrence R. Burke, Jr. & Peter P. Roller: Development of Efficient Two-Step Deprotection Methodology for Dimethyl-Protected Phosphoamino Acid-Containing Peptide Resins and Its Application to the Practical Synthesis of Phosphopeptides. J. Org. Chem.. 1995; 60 3967-3974.

  9. Akira Otaka, Kengo Miyoshi, Peter P. Roller, Terrence R. Burke, Jr., Hirokazu Tamamura & Nobutaka Fujii: Practical Synthesis of Phosphopeptides using Dimethyl-protected Phosphoamino Acid Derivatives. J. Chem. Soc., Chem. Commun.. 1995; 387-389.

  10. Toshiro Ibuka, Kazuo Nakai, Hiromu Habashita, Yuka Hotta, Akira Otaka, Hirokazu Tamamura, Nobutaka Fujii, Norio Mimura, Yoshihisa Miwa, Tooru Taga, Yukiyasu Chounan & Yoshinori Yamamoto: Aza-Payne Rearrangement of Activated 2-Aziridinemethanols and 2,3-Epoxy Amines under Basic Conditions. J.Org.Chem.. 1995; 60 2044-2058.

  11. Kazuo Nakai, Toshiro Ibuka, Akira Otaka, Hirokazu Tamamura, Nobutaka Fujii & Yoshinori Yamamoto: A One-pot Aza-Payne Rearrangement-Epoxide Ring Opening Reaction of 2-Aziridinemethanols: A Regio- and Stereoselective Synthetic Route to Diastereomerically Pure 1,2-Amino Alcohols. Tetrahedron Lett.. 1995; 36 6247-6250.

  1. Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N, et al.: Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun. 1994.12; 205 (3): 1729-1735. ( PubMed )

  2. Shimizu T, Uenishi H, Teramura Y, Iwashiro M, Kuribayashi K, Tamamura H, Fujii N, Yamagishi H: Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. J Virol. 1994.12; 68 (12): 7704-7708. ( PubMed )

  3. Otaka A, Tamamura H, Terakawa Y, Masuda M, Koide T, Murakami T, Nakashima H, Matsuzaki K, Miyajima K, Ibuka T, et al.: Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II). Biol Pharm Bull. 1994.12; 17 (12): 1669-1672. ( PubMed )

  4. Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Matsumoto A, Yamamoto N, Fujii N: Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide. Biochem Biophys Res Commun. 1994.07; 202 (1): 470-475. ( PubMed )

  5. Nobutaka Fujii, Kazuo Nakai, Hiromu Habashita, Yuka Hotta, Hirokazu Tamamura, Akira Otaka & Toshiro Ibuka: Synthesis of Optically Pure 2-Aziridinemethanols: Versatile Synthetic Building Blocks. Chem. Pharm. Bull.. 1994; 42 2241-2250.

  6. Toshiro Ibuka, Keisuke Suzuki, Hiromu Habashita, Akira Otaka, Hirokazu Tamamura, Norio Mimura, Yoshihisa Miwa, Tooru Taga & Nobutaka Fujii: (E)-Stereoselective Synthesis of Vinylglycines from (R)-Serine via Organocopper-BF3 and Related Reagents. J. Chem. Soc., Chem. Commun.. 1994; 2151-2152.

  1. Tamamura H, Kuroda M, Masuda M, Otaka A, Funakoshi S, Nakashima H, Yamamoto N, Waki M, Matsumoto A, Lancelin JM, et al.: A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. Biochim Biophys Acta. 1993.05; 1163 (2): 209-216. ( PubMed )

  2. Tamamura H, Ikoma R, Niwa M, Funakoshi S, Murakami T, Fujii N: Antimicrobial activity and conformation of tachyplesin I and its analogs. Chem Pharm Bull (Tokyo). 1993.05; 41 (5): 978-980. ( PubMed )

  3. Tamamura H, Nakamura J, Noguchi K, Funakoshi S, Fujii N: Acceleration of the N alpha-deprotection rate by the addition of m-cresol to diluted methanesulfonic acid and its application to the Z(OMe)-based solid-phase syntheses of human pancreastatin-29 and magainin 1. Chem Pharm Bull (Tokyo). 1993.05; 41 (5): 954-957. ( PubMed )

  4. Toshiro Ibuka, Tooru Taga, Hiromu Habashita, Kazuo Nakai, Hirokazu Tamamura, Nobutaka Fujii, Yukiyasu Chounan, Hisao Nemoto & Yoshinori Yamamoto : Syn-SN2' Pathway in the Reaction of Certain γ-(Mesyloxy)-α,β-Enoates with RCu(CN)MgX.BF3 Reagents. Importance of MgX and Bulky R Group upon the Diastereoselectivity. J. Org. Chem.. 1993; 58 1207-1214.

  5. Hirokazu Tamamura, Akira Otaka, Junko Nakamura, Kaori Okubo, Takaki Koide, Kyoko Ikeda & Nobutaka Fujii.: Disulfide Bond Formation in S-Acetamidomethyl Cysteine-Containing Peptides by the Combination of Silver Trifluoromethanesulfonate and Dimethylsulfoxide / Aqueous HCl. Tetrahedron Lett.. 1993; 34 4931-4934.

  1. Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, Terakawa Y, Tamamura H, Ibuka T, Murakami T, et al.: A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem Biophys Res Commun. 1992.12; 189 (2): 845-850. ( PubMed )

  1. Miyasaka K, Funakoshi A, Kitani K, Tamamura H, Funakoshi S, Fujii N: Inhibitory effect of pancreastatin on pancreatic exocrine secretions. Pancreastatin inhibits central vagal nerve stimulation. Gastroenterology. 1990.12; 99 (6): 1751-1756. ( PubMed )

  2. Tamamura H, Ohta M, Yoshizawa K, Ono Y, Funakoshi A, Miyasaka K, Tateishi K, Jimi A, Yajima H, Fujii N, et al.: Isolation and characterization of a tumor-derived human protein related to chromogranin A and its in vitro conversion to human pancreastatin-48. Eur J Biochem. 1990.07; 191 (1): 33-39. ( PubMed )

  3. Miyasaka K, Funakoshi A, Kitani K, Tamamura H, Fujii N, Funakoshi S: The importance of the C-terminal amide structure of rat pancreastatin to inhibit pancreatic exocrine secretion. FEBS Lett. 1990.04; 263 (2): 279-280. ( PubMed )

  4. Miyasaka K, Funakoshi A, Yasunami Y, Nakamura R, Kitani K, Tamamura H, Funakoshi S, Fujii N: Rat pancreastatin inhibits both pancreatic exocrine and endocrine secretions in rats. Regul Pept. 1990.04; 28 (2): 189-198. ( PubMed )

  5. Akihiro Funakoshi, Kyoko Miyasaka, Kenichi Kitani, Susumu Funakoshi, Hirokazu Tamamura, Nobutaka Fujii, Itsuro Nakano & Kazuhiko Tatemoto: Comparative Effects of Mammalian Pancreastatin on the Pancreatic Exocrine Secretion. Japanese J. Pysiol.. 1990; 39 901-905.

  1. Tateishi K, Funakoshi A, Wakasugi H, Iguchi H, Shinozaki H, Abe M, Funakoshi S, Tamamura H, Yajima H, Matsuoka Y: Plasma pancreastatin-like immunoreactivity in various diseases. J Clin Endocrinol Metab. 1989.12; 69 (6): 1305-1308. ( PubMed )

  2. Tateishi K, Funakoshi A, Jimi A, Funakoshi S, Tamamura H, Yajima H, Matsuoka Y: High plasma pancreastatinlike immunoreactivity in a patient with malignant insulinoma. Gastroenterology. 1989.11; 97 (5): 1313-1318. ( PubMed )

  3. Funakoshi S, Tamamura H, Ohta M, Yoshizawa K, Funakoshi A, Miyasaka K, Tateishi K, Tatemoto K, Nakano I, Yajima H, et al.: Isolation and characterization of a tumor-derived human pancreastatin-related protein. Biochem Biophys Res Commun. 1989.10; 164 (1): 141-148. ( PubMed )

  4. Funakoshi A, Jimi A, Yasunami Y, Tateishi K, Funakoshi S, Tamamura H, Yajima H: Bioactivity of human pancreastatin and its localization in pancreas. Biochem Biophys Res Commun. 1989.03; 159 (3): 913-918. ( PubMed )

  5. Funakoshi A, Miyasaka K, Kitani K, Tamamura H, Funakoshi S, Yajima H: Bioactivity of synthetic C-terminal fragment of rat pancreastatin on endocrine pancreas. Biochem Biophys Res Commun. 1989.02; 158 (3): 844-849. ( PubMed )

  6. Nobutaka Fujii, Akira Otaka, Toshihiro Watanabe, Akira Okamachi, Hirokazu Tamamura, Haruaki Yajima, Yoshimasa Inagaki, Motoyoshi Nomizu & Katsuhiko Asano: Silver Trifluoromethanesulphonate as an S-Deprotecting Reagent for the Synthesis of Cystine Peptides. J. Chem. Soc., Chem. Commun.. 1989; 283-284.

  1. Funakoshi A, Miyasaka K, Nakamura R, Kitani K, Funakoshi S, Tamamura H, Fujii N, Yajima H: Bioactivity of synthetic human pancreastatin on exocrine pancreas. Biochem Biophys Res Commun. 1988.11; 156 (3): 1237-1242. ( PubMed )

  2. Susumu Funakoshi, Hirokazu Tamamura, Nobutaka Fujii, Kumi Yoshizawa, Haruaki Yajima, Kyoko Miyasaka, Akihiro Funakoshi, Mitsuhiro Ohta, Yoshimasa Inagaki & Louis A. Carpino: Combination of a New Amide-precursor Reagent and Trimethylsilyl Bromide Deprotection for the Fmoc-based Solid Phase Synthesis of Human Pancreastatin and One of its Fragment. J. Chem. Soc., Chem. Commun.. 1988; 1588-1590.

  1. 小早川 拓也: 医薬化学　SARS-CoV-2パパイン様プロテアーゼに対する共有結合性阻害薬の開発 ファルマシア. 2024.03; 60 (3): 235. ( 医中誌 )

  1. 玉村 啓和: HIVの研究を基盤とした抗SARS-CoV-2剤の創製 MEDCHEM NEWS. 2023.11; 33 (4): 187-192.

  2. Kobayakawa Takuya, Amano Masayuki, Nakayama Miyuki, Tsuji Kohei, Ishii Takahiro, Miura Yutaro, Shinohara Kouki, Yamamoto Kenichi, Matsuoka Masao, Tamamura Hirokazu: Development of anti-HBV agents targeting HBV capsid proteins RSC MEDICINAL CHEMISTRY. 2023.08; 14 (10): 1973-1980. ( PubMed , DOI )

  3. 玉村 啓和: 創薬を先導する中分子ペプチド 月刊「細胞」. 2023.07; 55 (9): 660-661.

  4. 小早川 拓也: ペプチドミメティックを活用したアミロイドβ凝集機構の解明と創薬展開 医科学応用研究財団研究報告. 2023.02; 40 295-299. ( 医中誌 )

  5. Kobayakawa Takuya, Yokoyama Masaru, Tsuji Kohei, Fujino Masayuki, Kurakami Masaki, Onishi Takato, Boku Sayaka, Ishii Takahiro, Miura Yutaro, Shinohara Kouki, Kishihara Yuki, Ohashi Nami, Kotani Osamu, Murakami Tsutomu, Sato Hironori, Tamamura Hirokazu: Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins RSC ADVANCES. 2023.01; 13 (3): 2156-2167. ( PubMed , DOI )

  1. Tsuji Kohei, Wang Rongyi, Owusu B. -A. Kofi, Kobayakawa Takuya, Murakami Tsutomu, Tamamura Hirokazu: Exploration of novel class anti-HIV-1 agents derived from a viral capsid protein JOURNAL OF PEPTIDE SCIENCE. 2022.08; 28

  2. Tsuji Kohei, Wang Rongyi, Owusu B. -A. Kofi, Kobayakawa Takuya, Murakami Tsutomu, Tamamura Hirokazu: Exploration of novel class anti-HIV-1 agents derived from a viral capsid protein JOURNAL OF PEPTIDE SCIENCE. 2022.08; 28

  3. 小早川 拓也, 辻 耕平, 玉村 啓和: 「ペプチドミメティックを活用した中分子型創薬リードの創製」 「月刊バイオインダストリー」特集“ペプチド医薬の最新動向～広い観点からのペプチド創薬科学～” 「監修 木曽 良明」. 2022.05; 39 (5): 69-84.

  4. 野村 渉, 玉村 啓和: 「HIV-1阻害剤・腫瘍認識プローブとしてのケモカイン受容体リガンド」 「月刊バイオインダストリー」特集“ペプチド医薬の最新動向～広い観点からのペプチド創薬科学～” 「監修 木曽 良明」. 2022.05; 39 (5): 15-25.

  1. 辻 耕平: 医薬化学　SARS-CoV-2メインプロテアーゼ(Mpro)を標的とした阻害薬開発の動向 ファルマシア（日本薬学会 東京）. 2021.12; 57 (12): 1133. ( 医中誌 )

  2. 玉村 啓和: 明日の創薬を先導する中分子「ペプチド」 ファルマシア オピニオン（日本薬学会 東京）. 2021.09; 57 (9): 791.

  3. 石井 貴大, 小早川 拓也, 松田 幸樹, 辻 耕平, 吉村 和久, 満屋 裕明, 前田 賢次, 玉村 啓和: HIV感染症の根治へ向けたDAG-ラクトン誘導体の構造活性相関研究 日本薬学会年会要旨集. 2021.03; 141年会 29V03-pm04S. ( 医中誌 )

  1. 小早川 拓也: Aβ凝集阻害を指向したペプチドミメティックの開発 上原記念生命科学財団研究報告集. 2020.12; 34 1-4. ( 医中誌 )

  2. 村上 努, 小早川 拓也, 倉上 真樹, 横山 勝, 小谷 治, 辻 耕平, 佐藤 裕徳, 玉村 啓和: カプシド二量体化を標的とした新規抗HIV-1低分子化合物の解析 日本エイズ学会誌. 2020.11; 22 (4): 461. ( 医中誌 )

  3. 玉村 啓和, 小早川 拓也, 辻 耕平: 環状ペプチドで標的細胞へターゲティングする 「Drug Delivery System」特集“中分子創薬とDDS”. 2020.07; 35 (3): 170-180.

  4. 玉村 啓和, 小早川 拓也, 辻 耕平: 【中分子創薬とDDS】環状ペプチドで標的細胞へターゲティングする Drug Delivery System. 2020.07; 35 (3): 170-180. ( 医中誌 )

  1. 松田 幸樹, 服部 真一朗, 土屋 亮人, 小早川 拓也, 潟永 博之, 吉村 和久, 岡 慎一, 遠藤 泰之, 玉村 啓和, 満屋 裕明, 前田 賢次: HIV再活性化に伴うアポトーシス誘導能を用いたHIVリザーバー除去に資する新たなShock&Kill療法の可能性 日本エイズ学会誌. 2019.11; 21 (4): 474. ( 医中誌 )

  2. 村上 努, 海老原 健人, 小早川 拓也, 藤野 真之, 児玉 栄一, 玉村 啓和: 二量体化HIV-1膜融合阻害剤の作用機構 日本エイズ学会誌. 2019.11; 21 (4): 427. ( 医中誌 )

  3. 小早川拓也, 玉村啓和: ペプチドミメティック 有機合成化学協会誌 十字路. 2019.09; 77 (9): 923.

  4. 小早川拓也, 玉村啓和: クロロアルケン骨格を基盤としたペプチドミメティック化学への展開 有機合成化学協会誌 総合論文. 2019.09; 77 (9): 904-911.

  5. 小早川拓也: オキセタニル骨格を活用したペプチドミメティック化学への展開 有機合成化学協会誌 Review de Debut. 2019.07; 77 (7): 720-721.

  1. 村上 努, 海老原 健人, 藤野 真之, 本田 柚子奈, 小早川 拓也, 野村 渉, 玉村 啓和: 二量体化に基づいた新規抗HIV-1膜融合阻害薬の創出 日本エイズ学会誌. 2018.11; 20 (4): 523. ( 医中誌 )

  2. 宮下 直樹, 奥平 桂一郎, 川原 遥華, 津田 雄介, 森本 恭平, 辻 耕平, 重永 章, 大高 章, 石田 竜弘: 動脈硬化治療を指向した光制御型HDL構成ペプチドの開発 日本薬剤学会年会講演要旨集. 2018.05; 33年会 179. ( 医中誌 )

  1. 松田 幸樹, 服部 真一朗, 土屋 亮人, 小早川 拓也, 大橋 南美, 野村 渉, 原田 恵嘉, 佐藤 賢文, 吉村 和久, 玉村 啓和, 満屋 裕明, 前田 賢次: HIV潜伏感染細胞を標的とした新規治療薬開発に有効なin vitro評価系の開発 日本エイズ学会誌. 2017.11; 19 (4): 403. ( 医中誌 )

  2. 原田 恵嘉, 野村 渉, 鳴海 哲夫, 横山 勝, 前田 賢次, 林 宏典, 紺野 奇重, 引地 優太, 佐藤 裕徳, 玉村 啓和, 俣野 哲朗, 吉村 和久: 網羅的Env標的阻害剤ライブラリーの構築(2) 日本エイズ学会誌. 2017.11; 19 (4): 401. ( 医中誌 )

  3. 松本 大亮, 野村 渉, 玉村 啓和: 化合物誘導型ゲノム編集技術の開発 日本バイオマテリアル学会大会予稿集. 2017.11; 39回 162. ( 医中誌 )

  4. 村上 努, 金子 萌美, 藤野 真之, 野村 渉, 玉村 啓和: カプシド蛋白質由来ペプチドを基にした新規抗HIV-1剤の創製 日本エイズ学会誌. 2017.11; 19 (4): 400. ( 医中誌 )

  5. 川原 遥華, 奥平 桂一郎, 宮下 直樹, 津田 雄介, 森本 恭平, 辻 耕平, 重永 章, 大高 章, 石田 竜弘: 光応答性アポリポタンパク質の開発 日本薬剤学会年会講演要旨集. 2017.05; 32年会 272. ( 医中誌 )

  6. Nomura W, Tamamura H: [ZIP tag-probe system: A fluorescence imaging tool for intercellular proteins]. Seikagaku. The Journal of Japanese Biochemical Society. 2017.02; 89 (1): 115-20. ( PubMed )

  7. 野村 渉, 玉村 啓和: 細胞内タンパク質を可視化するタグ　蛍光プローブシステム 生化学. 2017.02; 89 (1): 115-119. ( 医中誌 )

  8. 野村　渉、玉村啓和: 細胞内タンパク質を可視化するタグ—蛍光プローブシステム 「生化学」みにれびゅう（日本生化学会　東京）. 2017.01; 89 (1): 1-6.

  1. 玉村啓和: 中分子創薬の可能性―ペプチドを創薬へと展開するー 現代化学. 2016; (6月号、543): 47-51.

  2. 大橋南美、玉村啓和: ペプチドミメティックを活用した中分子創薬の研究 化学工業　特集「ペプチド化学の最前線(I)」. 2016; 67 (10): 9-17.

  3. 野村　渉，玉村啓和: 多価型CXCR4リガンドの創製とがん細胞イメージング・検出 医学のあゆみ　第5土曜特集「GPCR研究の最前線2016」. 2016; 256 (5): 430-437.

  1. 小早川 拓也: 有機銅試薬によるクロロアルケン類の立体選択的合成法の開発とその応用 国立大学法人 東京医科歯科大学. 2014.03;

  2. 玉村啓和: ペプチドミメティックスを活用した抗HIV剤の創製 MEDCHEM NEWS（日本薬学会 医薬化学部会　東京）. 2014; 24 (1): 14-19.

  1. 玉村啓和: ケミカルバイオロジーを基盤とした抗HIV剤の創製. 薬学雑誌レビュー. 2012; 132 (1): 69-78. ( PubMed )

  2. 野村　渉、田中智博、相川春夫、玉村啓和: 最新ペプチド合成技術とその創薬研究への応用. 多価結合型GPCRリガンドの合成とがん細胞イメージングへの応用(株式会社　メディカルドゥ). 2012; 267-273.

  3. 野村渉、田中智博、相川春夫、玉村啓和: 多価結合型GPCRリガンドの合成とがん細胞イメージングへの応用 遺伝子医学MOOK[21]「最新ペプチド合成技術とその創薬研究への応用」. 2012; 267-273.

  1. 鳴海哲夫、玉村啓和: ペプチドミメティックによる創薬研究. 生化学. 2010.06; 82 (6): 515-523. ( PubMed )

  2. 野村　渉、増田朱美、玉村啓和: エピジェネティクな遺伝子発現制御のためのDNAメチル化酵素の創製. 生化学. 2010.05; 82 (5): 393-397. ( PubMed )

  1. 玉村啓和: ケモカインレセプターCXCR4をターゲットとしたペプチド創薬研究 薬学研究の進歩. 2009; (25): 33-38. ( 医中誌 )

  2. 玉村啓和: 種々の作用点をターゲットとした抗HIV剤の創製. 日本エイズ学会誌　（日本エイズ学会）. 2009; 11 (2): 100-101.

  1. 玉村啓和: 【統合創薬の開拓】　抗ウイルス薬・抗AIDS(HIV)薬 BIO Clinica. 2006; 21 (3): 224-230. ( 医中誌 )

  2. 玉村啓和: 【ポストゲノム時代の有機化学】　プロテインキナーゼC(PKC)を標的としたDiacylglycerolの環化誘導体の創製 ファルマシア. 2006; 42 (5): 431-435. ( 医中誌 )

  1. 藤井信孝, 大高章, 玉村啓和: 【飛躍するケミカルバイオロジー　化学から生命現象を明らかに】　ケミカルプロテオミクスによる創薬基盤の革新　情報から制御へ 細胞工学. 2005; 24 (11): 1181-1186. ( 医中誌 )

  1. 玉村　啓和: ケモカイン受容体を標的とした抗HIV剤の開発状況 最新医学. 1998; 53 (9): 2040-2046.

このページの先頭へ▲